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ABSTRACT 
 
Vitamin B12 or Cobalamin is structurally the most complex of all the vitamins. The 
entire biosynthetic pathway of cobalamin is well studied except the formation of the lower 
ligand known as dimethylbenzimidazole (DMB). 
In aerobic pathway, BluB catalyzes the formation of DMB using reduced flavin 
mononucleotide (FMNH2) as its substrate leading to the formation of DMB and erythrose-
4-phosphate as the end products. It is a remarkable transformation, wherein, C2 of DMB 
is derived from C1'  of the ribose sugar chain of FMN. However, the fate of the ring C of 
FMN moiety as well as the overall mechanism of this unique reaction is still unknown. 
Thus, identification of the final unknown product and a detailed mechanistic study of 
dimethylbenzimidazole formation is the main focus of this work. 
  In this dissertation, we have successfully identified alloxan as the end product 
derived from the third ring of FMN. Water and molecular oxygen have been shown to be 
the two sources of oxygen atom incorporation in alloxan based on O-18 labeling studies.  
A key intermediate in our mechanistic proposal has been successfully trapped in 
the form of six different shunt products using water, bisulfite and hydride as nucleophiles. 
Trapping of this intermediate helps us establish that the C-C bond cleavage occurs first 
forming erythrose-4-phosphate followed by the release of alloxan. Asp-32 has been shown 
to play an important role in stabilizing this intermediate  
Based on stereochemical studies, we have shown that the pro-R hydrogen is 
selectively abstracted from the C1' of the ribityl chain of the substrate. This result helps us 
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establish that the final oxidation step involved in DMB formation is indeed catalyzed by 
the enzyme. Formation of a new shunt product was observed on using 8-substituted flavins 
as substrate analogs for the BluB catalyzed reaction. Characterization of this shunt product 
provides evidence for the initial fragmentation of the peroxyflavin intermediate involved 
in the DMB biosynthesis. 
All these above observations are consistent with our current mechanistic proposal 
for the DMB formation. Thus, we have finally unraveled the long unsolved mystery in the 
Vitamin B12 biosynthesis. 
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NOMENCLATURE 
 
FMN Flavin Mononucleotide 
DMB Dimethylbenzimidazole 
FAD Flavin Adenine Dinucleotide 
CIP Calf Intestinal Phosphatase 
CTP Cytidine Triphosphate 
ATP Adenosine Triphosphate 
oPDA o-Phenylenediamine 
PFBHA o-(pentafluorobenzyl)hydroxylamine 
NADH Nicotinamide Adenine Dinucleotide (Reduced form) 
SAM S-Adenosyl-L-methionine 
NMR Nuclear Magnetic Resonance 
EIC Extracted Ion Chromatogram 
HPLC High Performance Liquid Chromatography 
LC-MS Liquid Chromatography Mass Spectroscopy 
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Figure 1. Structure of Vitamin B12 
CHAPTER I  
INTRODUCTION  
 
1.1 Vitamin B12 
Vitamin B12 or Cobalamin (1) is structurally the most complex of all the vitamins 
and one of the largest non-polymeric natural products1,2. The core consists of a modified 
tetrapyrrole ring, known as the corrin ring, with a cobalt ion chelated at its center (Figure 
1). The cobalt ion is coordinated to the four nitrogen atoms of the pyrrole rings along with 
two other ligands. The upper axial ligand varies, wherein, 5' -deoxyadenosyl 
(adenosylcobalamin), methyl (methylcobalamin) and cyano (cyanocobalamin) groups are 
usually seen. The lower ligand, covalently attached to the corrin ring by a nucleotide loop, 
is generally 5,6-dimethylbenzimidazole (DMB).  
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Vitamin B12 plays a vital role in the proper functioning of the brain and nervous 
system and is also involved in the fatty and amino acid metabolism. Deficiency of 
cobalamin leads to pernicious anemia. It is an autoimmune disease in which the parietal 
cells of the stomach are destroyed. These parietal cells are responsible for secreting the 
intrinsic factor which plays a major role in the absorption of vitamin B12. Thus, a lack of 
intrinsic factor leads to vitamin B12 deficiency resulting in pernicious anemia. 
Cobalamin also acts as an essential co-factor in several enzyme catalyzed reactions. 
Currently, the B12-dependent enzymes are broadly classified into three groups: isomerases, 
methyltransferases and dehalogenases3. Two of the most notable examples in which 
vitamin B12 acts as a co-factor are shown below in Figure 2. 
1. Methylmalonyl CoA mutase: Catalyzes the isomerization of methylmalonyl CoA 
to succinyl CoA. 
2. Methionine synthase: Catalyzes the synthesis of methionine from homocysteine.  
 
 
 
 
 
 
 
 
 
Figure 2. Examples of Vitamin B12-dependent enzymes 
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1.2 Biosynthesis of dimethylbenzimidazole (DMB) 
The entire biosynthetic pathway of cobalamin is well studied except the formation 
of DMB which is the last unsolved puzzle in vitamin B12 biosynthesis
4-8. Recently, it has 
been shown that in anaerobic organisms, BzaF is involved in the biosynthesis of 
benzimidazole9-12. BzaF is a radical SAM enzyme which catalyzes the formation of 5-
hydroxybenzimidazole (5-HBI, 7) from aminoimidazole ribotide (AIR, 6) (Figure 3)13,14. 
 
 
 
 
 
 
 
 
 
In the aerobic pathway, BluB has been identified as the enzyme which catalyzes 
the formation of dimethylbenzimidazole (DMB) using reduced flavin mononucleotide 
(FMNH2, 12) as its substrate
15-17. BluB catalyzes the unprecedented fragmentation of the 
flavin molecule in the presence of oxygen leading to the formation of DMB (13) and 
erythrose-4-phosphate (14) as the end products (Figure 4)18,19. It is a remarkable 
transformation, wherein, C2 of DMB is derived from C1'  of the ribose sugar chain of FMN 
(shown as a black circle) based on previous labeling studies20-24.  
Figure 3. BzaF catalyzed conversion of AIR to 5-HBI 
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1.3 Active site structure of BluB 
The crystal structure of BluB (PDB code: 2ISL) shows a close resemblance to the 
flavin oxidoreductase and nitroreductase enzyme superfamily having conserved active site 
residues25,26. In striking contrast to the oxidoreductases and nitroreductases, the active site 
of BluB consists of an extended lid which completely sequesters FMN from the external 
solvent. Such a structural motif is also seen in the iodotyrosine deiodinase (IYD) which 
carries out reductive dehalogenation using reduced FMN (FMNH2) as a cofactor
27. Though 
structurally similar, BluB shows completely different function as compared to 
oxidoreductase, nitroreductase and IYD28,29.  
The key active site residues of BluB and their interactions with the substrate 
FMNH2 are shown in Figure 5
30. The phosphate group forms H-bonds with the residues 
Arg-30 and Arg-31. The active site of BluB consists of residues which are conserved 
among the BluB orthologs but are absent in oxidoreductases. Asp-32 and Ser-167 are two 
such residues which are very critical for the catalytic activity of BluB and mutation of 
these residues results in loss of activity. Oxidoreductase, nitroreductase and IYD enzymes 
generally have a serine or arginine residue to stabilize the N1 of FMN by H-bonding. In 
Figure 4. Scheme for BluB catalyzed DMB formation 
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Figure 5. Active site structure of BluB 
BluB, however, along with Arg-34 there is also Asp-32 which is in proximity to N1 of 
FMN as well as C1' of the ribityl chain. Ser-167 forms hydrogen bonding with N5 of flavin 
in the BluB active site. Such an interaction is also seen in IYD where the serine is replaced 
by threonine. Interestingly, mutation of threonine to alanine in IYD results in a switch of 
its functionality from being a dehalogenase to a nitroreductase31. In oxidoreductases, 
however, hydrogen bonding to N5 of flavin is achieved by the protein amide backbone. 
The nature of H-bonding to N5 of flavin, thus, seems to dictate the function carried out by 
the enzyme. H-bonding between N5 and amide backbone leads to two-electron reduction 
chemistry (oxidoreductases and nitroreductases) while the bonding with a side chain 
hydroxyl group results in a one-electron chemistry (BluB and IYD)32.  
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1.4 Mechanistic proposals for dimethylbenzimidazole formation in the literature 
BluB is a unique enzyme, wherein, fragmentation of one cofactor leads to another. 
The overall transformation from FMN to DMB represents a very complex and unusual 
reaction. Two mechanistic hypotheses have been proposed in the literature for this 
remarkable rearrangement15.  
 
 
 
 
 
 
 
 
In mechanism A, the flavin initially reacts with O2 to form the flavin hydroperoxide 
(15) which then undergoes hydroxylation at C1' of the ribityl chain assisted by the 
deprotonation at C1' using the Asp-32 residue (Figure 6). This seems to be a difficult step 
as hydroxylation at C1' requires a significant conformational change in the active site as 
Figure 6. Mechanistic proposal (A) for DMB formation15 
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well as the Asp-32 does not appear to be a strong enough base. This hydroxylation step is 
then followed by the Ser-167 mediated fragmentation of the flavin molecule to form 
intermediate 17 which then tautomerizes and undergoes C-C bond cleavage between the 
C1' and C2' of the ribose sugar chain in a retro-aldol fashion forming species 19 and 
erythrose-4-phosphate (14). The intermediate 19 then cyclizes and ultimately leads to the 
formation of DMB (13). 
 
 
 
 
 
 
 
 
 
 
 
 
In mechanism B, the flavin hydroperoxide (15) formed initially is proposed to 
undergo fragmentation by a hydride transfer from the hydroxyl group at C2' of the ribityl 
tail leading to the C1' -C2' bond cleavage (Figure 7). Such a hydride transfer is 
Figure 7. Mechanistic proposal (B) for DMB formation15 
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unprecedented, and even the hydroxyl groups are not known to form hydride ions as 
proposed in this mechanism. This unusual step leads to the formation of erythrose-4-
phosphate (14) and the intermediate 26. Asp-32 has been suggested to play a key role in 
stabilizing the positive charge at C1' position in 26 or the stabilization of the transition state 
leading to 26. The intermediate 26 is transformed to 27 with the assistance of Ser-167 
which then undergoes cyclisation to yield the species 28. Hydrolysis of 28 leads to the 
formation of alloxan (29) and intermediate 30 which finally undergoes oxidation to yield 
DMB (13). 
The first step in both the above proposals is the formation of the flavin hydroperoxy 
species (15) from the substrate FMNH2 in the presence of O2. However, the subsequent 
fragmentation of the flavin peroxy moiety involves unusual steps which seem to be very 
challenging in both these mechanisms. Due to this limitation, a third alternate mechanism 
(Figure 8) has been proposed in the literature based on model chemistry33,34.  
In this proposal, the peroxy flavin (15) undergoes Baeyer-Villiger rearrangement 
to form the intermediate 32 followed by repeated hydrolysis to form 33. 33 undergoes 2-
electron oxidation forming the bisimine (34) followed by a retro-aldol C-C bond cleavage 
to form 3535. Cyclisation followed by oxidation leads to DMB (13) formation. 
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1.5 Research opportunity 
Three mechanisms exist in the literature for the BluB catalyzed DMB formation 
based on the labeling studies and crystal structure. However, the fate of the ring C of the 
FMN moiety is still unknown, and a complete mechanistic characterization is still desired 
for this unique transformation.  
Figure 8. Mechanistic proposal (C) for DMB formation33,35 
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CHAPTER II 
IDENTIFICATION AND CHARACTERIZATION OF THE UNKNOWN PRODUCT 
IN THE BLUB CATALYZED REACTION  
 
2.1 Introduction 
 In aerobic organisms, BluB is involved in the biosynthesis of 
dimethylbenzimidazole (DMB) using reduced FMN (FMNH2) as its substrate. Oxygen is 
utmost necessary for the catalytic activity of BluB leading to the formation of DMB and 
erythrose-4-phosphate as the end products. However, the product(s) derived from the third 
ring of FMN are still unknown. In the last chapter, we have discussed the three mechanistic 
hypotheses which have been proposed in the literature for this complex reaction. No 
evidence has been provided to substantiate these proposals. Thus, along with the 
identification of the product(s) arising from the third ring of FMN, a detailed study is 
required to investigate the mechanism of DMB biosynthesis. 
 
2.2 Results and Discussion 
2.2.1 Identification of the unknown product(s) based on NMR studies 
 13C labeled FMN molecules, having the carbons in the third ring as 13C labeled, 
were designed to figure out the product(s) derived from the ring C of FMN36. Thus, three 
different 13C FMN isotopologues were synthesized: 4a-13C FMN, 2-13C FMN and 4,10a-
13C FMN (Figure 9)37. 
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Next, BluB enzymatic reactions were carried out using isotopically labeled FMN 
as substrate, and the reaction mixture was analyzed by 13C NMR spectroscopy (Figure 10). 
A new peak was observed at 85.3 ppm in 13C NMR on using [4a-13C] FMN as substrate 
(Figure 10A). When [2-13C] FMN was used, a new peak was seen at 159.5 ppm (Figure 
10B) while on using [4,10a-13C] FMN two new peaks were observed at 171 and 177 ppm 
(Figure 10C). Several compounds were tested as possible candidates for the new product 
derived from the ring C such as urea, bicarbonate, oxalic acid, alloxan, alloxanic acid and 
dialuric acid. Finally, alloxanic acid (37) was found as the unknown product as its 13C 
NMR spectra aligned exactly with the spectra obtained in case of BluB reactions (Figure 
10D).  This was further confirmed by spiking the reaction mixture with the alloxanic acid 
standard (Figure 10E). Thus, alloxanic acid seemed to be the final unknown product in the 
BluB catalyzed reaction based on the NMR results. 
Figure 9. Various 13C FMN isotopologues synthesized 
 12 
 
Figure 11. Mechanism of rearrangement of alloxan (29) to alloxanic acid (37) 
 
 
 
 
 
 
 
 
 
 
2.2.2 Identification of the unknown product by derivatization reaction 
Alloxan (29) has been reported in the literature to readily undergo rearrangement 
to alloxanic acid (37) under alkaline conditions (Figure 11)38-40. 
 
 
 
 
 
 
 
 
 
A) BluB + [4a-13C] 
B) BluB + [2-13C] 
C) BluB + [4,10a-13C] 
D) Alloxanic acid standard 
E) (C) + (D) 
Figure 10. 13C NMR spectra of BluB catalyzed reactions. (A) Enzymatic reaction using [4a-13C] FMN (B) 
Enzymatic reaction using [2-13C] FMN (C) Enzymatic reaction using [4,10a-13C] FMN (D) Alloxanic acid 
standard (E) Enzymatic reaction using [4,10a-13C] FMN spiked with alloxanic acid standard 
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The pH of the phosphate buffer used in our enzymatic reactions was 7.5 which is 
sufficient to facilitate the rearrangement of alloxan to alloxanic acid. So, the question we 
had to address was whether alloxan or alloxanic acid is the actual end product of the BluB 
catalyzed reaction. Alloxan can be easily trapped in the form of an adduct (40) using 
derivatizing agents such as o-phenylenediamine (oPDA, 39) (Figure 12).  
 
 
 
 
 
 
 
 
 
Next, enzymatic reactions were carried out in the presence of oPDA and were 
analyzed for the formation of the alloxan-oPDA adduct. Adduct formation was seen only 
in case of reaction carried out in the presence of oPDA (blue trace in the HPLC 
chromatogram, Figure 13A) and was absent in all the controls as well in the reaction 
carried out in the absence of oPDA (black trace). Formation of the alloxan-oPDA adduct 
was further confirmed by conducting coelution studies with the synthesized standard 
(Figure 13B) and by LC-MS analysis (Figure 14)41.  
 
 
 
 
Figure 12. Trapping of alloxan using o-phenylenediamine (oPDA) 
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Figure 14. LC-MS analysis of BluB catalyzed reaction in presence of o-phenylenediamine (oPDA). (A) 
Extracted Ion Chromatogram (EIC) at m/z 231.0524 showing the formation of alloxan-oPDA adduct only in 
case of full reaction carried out in presence of oPDA (Red trace) (B) ESI-MS of 40 in the negative mode 
11 12 13 14 15 16 17 18 19 Time [min]
0.00
0.25
0.50
0.75
1.00
1.25
5x10
Intens.
FR BluB_1-C,4_01_22650.d: EIC 231.0518±0.01 -All MS No BluB + oPDA_1-D,1_01_22656.d: EIC 231.0518±0.01 -All MS
No FMN + oPDA_1-C,7_01_22653.d: EIC 231.0518±0.01 -All MS No NADH + oPDA_1-C,9_01_22655.d: EIC 231.0518±0.01 -All MS
FR BluB + oPDA_1-D,2_01_22657.d: EIC 231.0518±0.01 -All MS
11           12             13            14             15            16             17             18        Time (mins)   
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0.75 
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0.25 
0.00 
 
Full Reaction No oPDA 
Full Reaction with oPDA 
 
No BluB 
No NADH 
No FMN 
A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on the results of the derivatization assays using oPDA, we can conclude that 
alloxan (29) is the actual end product of the BluB catalyzed reaction and was just 
rearranged to form alloxanic acid (37) in our NMR studies.  
B) 
231.0525 
 
Figure 13. HPLC analysis of BluB catalyzed reactions in presence of o-phenylenediamine (oPDA). (A) 
Formation of alloxan-oPDA adduct (40) seen only in case of full reaction carried out in presence of oPDA 
(B) Coelution data for the alloxan-oPDA adduct (40) formation 
 
B) 
  
A) 
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Alloxan, being the final end product, has been proposed in only one of the three 
mechanisms postulated in the literature. In only mechanism B, alloxan has been suggested 
as the final product though no evidence has been provided for such a proposal while the 
mechanisms A and C have hypothesized different end products. Identification of alloxan, 
thus, rules out the mechanisms A and C of the literature. Though mechanism B proposes 
alloxan as one of the products, the hydride transfer involved in the fragmentation of the 
flavin peroxy moiety seems to be a difficult step which makes this mechanism implausible.  
 
2.2.3 Trapping of the sugar product, erythrose-4-phosphate (14) 
Formation of DMB involves the cleavage of the ribose side chain. The ribose-
derived fragment was previously identified as erythrose-4-phosphate (14) by radio TLC 
and 31P NMR analysis15. As radio TLC is a low-resolution separation technique, the 
analysis was repeated using high resolution LC-MS to be certain of the stereochemical 
assignment as this is important for the mechanistic analysis. The carbohydrate product was 
trapped as an oxime using o-(pentafluorobenzyl)hydroxylamine (PFBHA, 41) as the 
derivatizing agent (Figure 15). The corresponding oxime (42) formation was seen only in 
case of the full reaction and was also confirmed by its standard (Figure 16). 
 
 
 
 
 
 
 Figure 15. Trapping of erythrose-4-phosphate using PFBHA 
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Thus, the complete scheme for the DMB formation is as shown in Figure 17. 
 
 
Thus, the complete scheme for the DMB formation is as illustrated in Figure 17. 
 
 
 
 
2.2.4 O-18 labeling studies for the source of oxygen incorporation in alloxan 
The end product alloxan formed has two additional oxygen atoms incorporated in 
it as compared to the starting material, FMN. On carrying out the enzymatic reaction in 
the presence of 18O2 gas, no O-18 incorporation was seen in the alloxan-oPDA adduct. 
However, when the reaction was performed using H2
18O buffer, a 2 Da increase in the 
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) 
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) 
Figure 16. LC-MS analysis for the trapping of erythrose-4-phosphate. (A) Extracted Ion Chromatogram 
(EIC) at m/z 394.0121 corresponding to erythrose-4-phosphate-PFBHA oxime (42) (B) ESI-MS of 42 in the 
negative mode 
Figure 17. Complete scheme for the formation of Dimethylbenzimidazole 
394.0134 
 
B)
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mass of the adduct was observed implying that one of the oxygen atoms in the alloxan is 
incorporated from water (Figure 18). 
 
 
 
 
 
 
 
 
 
We propose that one of the oxygen atoms in alloxan comes from water (atom 
labeled in pink) whereas the other one is incorporated from oxygen gas (atom labeled in 
blue) (Figure 19). 
 
 
 
 
 
 
B) 
H2
18O 
233.0573 
 
231.0531 
 
A) 
18O2 
231.0529 
 
Figure 19. O-18 labeling pattern in alloxan 
Figure 18. LC-MS analysis of BluB reaction in (A) 18O2 gas and (B) H218O buffer 
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However, no O-18 incorporation was seen in the adduct on carrying out the reaction 
using 18O2 gas. This result can be attributed to the fact that on trapping alloxan using oPDA, 
an imine type intermediate (43) is formed first wherein the oxygen atom incorporated from 
oxygen gas is lost in the form of water. This intermediate further undergoes rearrangement 
to form the final adduct (40) in which the oxygen atom incorporated from water is still 
retained as seen in the mass data (Figure 20). 
 
 
 
 
 
 
 
 
 
2.2.5 Mechanistic proposal for DMB biosynthesis 
Based on all these observations, our current mechanistic proposal for the DMB 
formation is as shown in Figure 21. 
We propose that the reduced flavin (FMNH2, 12) first reacts with molecular oxygen 
to form the well-characterized species flavin hydroperoxide (15). The flavin 
hydroperoxide then undergoes fragmentation to form species 46 via 45. The hydroxide 
released during the peroxide fragmentation (46 to 47) deprotonates the ribose alcohol and 
triggers a retro-aldol reaction leading to a C-C bond cleavage between the C1' and C2' of 
Figure 20. Mechanism of trapping of alloxan using o-phenylenediamine (oPDA) 
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the ribose sugar chain to form intermediate 27 with the subsequent release of erythrose-4-
phosphate (14) as one of the end products. The species 27 then undergoes hydrolysis to 
form 48 followed by a C-N bond cleavage to form 35 and alloxan (29). Intermediate 35 
finally undergoes cyclization forming 30 followed by oxidation to form the end product 
dimethylbenzimidazole (13).  
 
  
 
 
 
 
 
 
  
 
 
 
 
Figure 21. Mechanistic proposal for the formation of dimethylbenzimidazole 
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2.3 Conclusion 
 In this chapter, we have successfully identified alloxan as the final unknown 
product of the BluB catalyzed reaction. We have also been able to establish that water and 
molecular oxygen are the two sources of oxygen atom incorporation in alloxan. The sugar 
end product, erythrose-4-phosphate, has been trapped using PFBHA as the derivatizing 
agent. Finally, a mechanistic hypothesis has been proposed based on our results for the 
biosynthesis of dimethylbenzimidazole. 
 
2.4 Experimental 
2.4.1 Materials 
All chemicals were purchased from Sigma-Aldrich unless mentioned otherwise. A 
dehydrated form of LB medium was purchased from EMD Millipore. IPTG, Kanamycin 
and Ampicillin were purchased from Lab Scientific Inc. HPLC and LCMS solvents were 
purchased from EMD and used without any further purification. Histrap column was 
obtained from GE Healthcare. Amicon ultra centrifugal filters (10,000 MWCO) were 
purchased from Millipore. Econo-Pack 10DG desalting columns were purchased from 
Bio-Rad. Protein overexpression was carried out in 2.5L baffled ultra yield flasks obtained 
from Thomson Instrument Company. H2
18O was purchased from Cambridge Isotope 
Laboratories. ZORBAX Eclipse XDB-C18 column (4.6 x 150 mm, 5μm particles) was 
obtained from Agilent Technologies. 
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2.4.2 Overexpression and purification of BluB  
The BluB gene, cloned in pET11t vector, was transformed into Escherichia coli 
BL21 (DE3) cell line. A 10 mL starter culture was grown at 37 oC containing 100 μg/mL 
Ampicillin for 6 hrs. 1.5 liters of LB media was inoculated with this starter culture. The 
cells were grown at 37 oC with shaking till the OD600 reached 0.6. The protein expression 
was then induced by adding IPTG (final concentration 1 mM) and the culture was 
incubated at 15 oC for 15 hrs. The cells were then harvested by centrifugation and 
resuspended in 30 mL of binding buffer (50 mM phosphate buffer containing 150 mM 
NaCl, 10mM imidazole, pH 7.8). The cells were lysed by sonication followed by 
centrifugation at 15000 rpm for 45 mins. The supernatant containing the soluble protein 
was loaded on a Ni-NTA affinity column (Histrap-GE Healthcare) and was then washed 
with 50 mL of wash buffer (50 mM phosphate buffer containing 150 mM NaCl, 20mM 
imidazole, pH 7.8). The protein was eluted with the elution buffer (100 mM phosphate 
buffer containing 100 mM NaCl, 250 mM imidazole, pH 7.8). The eluted protein fractions 
were pooled and concentrated using 10kDa Amicon ultracentrifugal filters to a final 
volume of 3 mL. The concentrated protein solution was buffer exchanged into 100 mM 
phosphate buffer containing 150 mM NaCl and 15% glycerol, pH 7.8 using an Econo-Pac 
10DG desalting column.  
 
2.4.3 Over-expression and purification of Riboflavin kinase (RibK)42,43 
The RibK gene, cloned in pT7-7 vector, was transformed into Escherichia coli 
BL21 (DE3) cell line. A 10 mL starter culture was grown at 37 oC containing 100 μg/mL 
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ampicillin for 6 hrs. 1.5 liters of LB media was inoculated with this starter culture. The 
cells were grown at 37 oC with shaking till the OD600 reached 0.6. The protein expression 
was then induced by adding IPTG (final concentration 1 mM) and the culture was 
incubated at 15 oC for 15 hrs. The cells were then harvested by centrifugation and 
resuspended in 30 mL of binding buffer (50mM KPi buffer containing 150 mM NaCl, 
10mM imidazole, pH 7.8). The cells were lysed by sonication followed by centrifugation 
at 15000 rpm for 45 mins. The supernatant was heated at 70 oC and the solution was 
centrifuged. The supernatant containing the soluble protein was concentrated using 10kDa 
Amicon ultracentrifugal filters to a final volume of 3 mL. The concentrated protein 
solution was buffer exchanged into 100 mM KPi buffer containing 150 mM NaCl and 15% 
glycerol, pH 7.8 using an Econo-Pac 10DG desalting column.  
 
2.4.4 HPLC parameters 
An Agilent 1260 HPLC equipped with a quaternary pump was used. The system 
included a diode array UV-Vis detector and eluted compounds were detected using 
absorbance at 254, 280, 260, 450, 320 and 340 nm. Analysis was performed on a ZORBAX 
Eclipse XDB-C18 column (4.6 x 150 mm, 5 μm particles, Agilent Technologies).  
 
2.4.5 HPLC conditions 
A: Water 
B: 10 mM ammonium acetate, pH 6.6 
C: Methanol 
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2.4.6 HPLC method 
The following gradient at a flow rate of 1 mL/min was used.  
0 min: 90% A, 10% B; 2 min: 90% A, 10% B; 17 min: 15% A, 10% B, 75% C; 23 min: 
15% A, 10% B, 75% C; 25 min: 90% A, 10% B; 30 min: 90% A, 10% B. 
 
2.4.7 LC-MS parameters 
LC-ESI-TOF-MS was performed using an Agilent 1260 HPLC system equipped 
with a binary pump and a 1200 series diode array detector followed by a MicroToF-Q II 
mass spectrometer (Bruker Daltonics) using an ESI source either in positive mode or 
negative mode. The analysis was performed on a Poroshell 120 EC-C18 column (3.0 x 100 
mm, 2.7 μm particles, Agilent Technologies).  
 
2.4.8 LC conditions 
A: 5 mM ammonium acetate buffer, pH 6.6 
B: 75% Methanol and 25% Water 
 
2.4.9 LC method (for both positive and negative mode on MS) 
The following gradient at a flow rate of 0.4 mL/min was used.  
0 min: 100% A, 0% B; 2 min: 100% A, 0% B; 12 min: 25% A, 75% B; 17 min: 25% A, 
75% B; 18.5 min: 100% A, 0% B; 30 min: 100% A, 0% B. 
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2.4.10 NMR studies of BluB catalyzed reactions  
BluB enzymatic reactions were performed in 100 mM phosphate buffer, pH 7.5 
containing BluB (100 μM), 13C labeled FMN (300 μM) and dithionite. The enzymatic 
reactions were incubated at room temperature for 4 hrs. The protein was removed by heat 
denaturation and the reaction mixture was analyzed by 13C NMR. 
 
2.4.11 Reconstitution of BluB using Fre-NADH as reducing system 
BluB enzymatic reactions were performed in 100 mM phosphate buffer, pH 7.5 
containing BluB (100 μM), FMN (500 μM), NADH (2 mM) and E. coli flavin reductase, 
Fre (200 nM). The enzymatic reactions were incubated at room temperature for 4 hrs. The 
protein was removed by heat denaturation and the reaction mixture was analyzed by HPLC 
and LC-MS. 
 
2.4.12 BluB reactions in the presence of o-phenylenediamine (oPDA) – Trapping of 
Alloxan 
BluB enzymatic reactions were performed in 100 mM phosphate buffer, pH 7.5 
containing BluB (100 μM), FMN (500 μM), NADH (2 mM), E. coli flavin reductase, Fre 
(200 nM) and oPDA (2 mM). The enzymatic reactions were incubated at room temperature 
for 4 hrs. The protein was removed by heat denaturation and the reaction mixture was 
analyzed by HPLC and LC-MS. 
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2.4.13 Trapping of the sugar product (14) 
BluB enzymatic reactions were performed in 100 mM phosphate buffer, pH 7.5 
containing BluB (100 μM), FMN (500 μM), NADH (2 mM) and E. coli flavin reductase, 
Fre (200 nM). The enzymatic reactions were incubated at room temperature for 4 hrs. The 
protein was removed by heat denaturation and o-(pentafluorobenzyl)hydroxylamine 
(PFBHA) (2mM) was added to the reaction mixture and was heated at 65 oC for 1 hr. The 
reaction mixture was then analyzed by LC-MS. 
 
2.4.14 BluB reactions in the presence of 18O2 and H2
18O 
Two identical samples were prepared each containing BluB (100 μM), FMN (500 
μM), NADH (2 mM), E. coli flavin reductase, Fre (200 nM) and oPDA (2 mM). One of 
the samples was prepared using H2
18O (final concentration H2
18O:H2
16O = 4:1) while the 
other which served as a control using H2
16O. Both the samples were incubated at room 
temperature for 4 hrs and were then analyzed by LC-MS. 
Two identical samples were prepared in an anaerobic glove box each containing 
BluB (100 μM), FMN (500 μM), NADH (2 mM), E. coli flavin reductase, Fre (200 nM) 
and oPDA (2 mM). One of the samples was exposed to 18O2 while the other, serving as a 
control, to 16O2. Both the samples were incubated at room temperature for 4 hrs and were 
then analyzed by LC-MS. 
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2.4.15 Synthesis of 13C labeled FMN isotopologues36,37 
 The general synthetic scheme for 13C labeled FMN is shown in Figure 22. Dr. 
Sameh H. Abdelwahed synthesized the 13C labeled FMN isotopologues (11a-c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Scheme for the synthesis of 13C labeled FMN 
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The scheme for the synthesis of 13C labeled FMN isotopologues: 4a-13C FMN, 2-
13C FMN and 4,10a-13C FMN is shown in Figure 23. 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Scheme for the synthesis of 13C labeled FMN isotopologues (A) 4a-13C FMN (B) 2-13C FMN 
(C) 4,10a-13C FMN 
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Procedure 
Synthesis of N-(D-ribityl)-3,4-dimethylaniline (52): 3,4-Dimethylaniline, 51 (152 
mg, 1.0 equiv.), D-ribose (450 mg, 3.0 equiv.) and sodium cyanoborohydride (126 mg, 2.0 
equiv.) were dissolved in anhydrous MeOH (15 mL). The mixture was refluxed at 80 oC 
for 2 days under argon atmosphere. Then the solvent was removed under reduced pressure 
and excess NaBH3CN was quenched using 1M HCl. The resulting mixture was neutralized 
using saturated NaHCO3 solution and concentrated under reduced pressure. The residue 
was purified by silica gel column chromatography using chloroform/methanol (98:2 to 
80:20). Yield: 74%. 1H NMR (400 MHz, CD3OD):  2.12 (s, 3H), 2.17 (s, 3H), 3.08 (dd, 
1H), 3.43 (dd, 1H), 3.60-3.81 (m, 4H), 3.91 (dd, 1H), 6.47 (dd, 1H), 6.55 (d, 1H), 6.88 (d, 
1H) ppm.  
Synthesis of N-(D-ribityl)-2-phenylazo-4,5-dimethylaniline (54): A solution of 
1.05 g (0.01 mole) of aniline (53) in 3 ml of 12 N hydrochloric acid and 10 mL of water 
was cooled to 0 oC. A total of 0.80 g of solid sodium nitrite was added at a rate such that 
the temperature of the solution did not exceed 3 oC. After the sodium nitrite had been 
added, the solution was kept at 0 oC for half an hour. To a suspension of 2.15 g (0.09 mole) 
of N-(D-ribityl)-3,4-dimethylaniline (52) in 20 mL of water, 6.1 mL of 12 N hydrochloric 
acid and 6.06 g of sodium acetate was added. The mixture was cooled to -5 oC and the 
diazotized aniline solution prepared above was added. The resulting solution was stirred 
at -5 oC for 1.5 hours and then at 0 to 5 oC for another 1.5 hours. After warming to 20 oC, 
a solution of 3.0 g of sodium acetate in 20 mL of water was added at a rate such that the 
pH remained between 3-3.5 and the temperature between 17-20 oC. After stirring the 
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resultant mixture overnight, water was removed under vacuum and the crude residue was 
purified by column chromatography. Yield: 45%. 1H NMR (400 MHz, CD3OD): δ ppm 
2.17 (s, 3H), 2.20 (s, 3H), 3.3-3.42 (m, 1H), 3.81−3.56 (m, 5H), 4.01 (m, 1H), 6.78 (s, 1H), 
7.4-7.6 (m, 4H), 7.82 (d, 2H) ppm.  
Synthesis of barbituric acid (50): In 25 mL bottomed flask fitted with a reflux 
condenser under argon atmosphere, 0.06 g of sodium was dissolved in 10 mL of dry 
methanol. To this solution, 0.4 g (0.5 moles) of diethyl malonate (49) was added followed 
by 0.15 g (0.025 moles) of dry urea (25) dissolved in 10 mL of dry methanol. The mixture 
was stirred and refluxed for 4 hrs. A white solid separated out rapidly. After the completion 
of the reaction, 20 mL of hot water (50 °C) was added followed by enough hydrochloric 
acid to make the solution acidic. The resulting clear solution was filtered, cooled and kept 
in the fridge overnight. The white product thus obtained was filtered and washed with 20 
mL of cold water and dried. Yield: 72–78 %. 
[5-13C] Barbituric acid: 1H NMR (400 MHz, CD3OD): H is exchangeable by deuterium. 
13C NMR (100 MHz, CD3OD):  39.90 ppm (13C enriched C). 
[2-13C] Barbituric acid: 1H NMR (400 MHz, CD3OD): H is exchangeable by deuterium. 
13C NMR (100 MHz, CD3OD):  151.80 ppm (13C enriched C). 
[4,6-13C] Barbituric acid: 1H NMR (400 MHz, CD3OD): H is exchangeable by 
deuterium. 13C NMR (100 MHz, CD3OD):  168.85 ppm (13C enriched C). 
Synthesis of Riboflavin (55): To N-ribityl-2-phenylazo-4,5-dimethyl aniline, 54 
(35 mg, 0.1 mmol) in a 10 mL round bottomed flask, 2 mL of n-butanol, barbituric acid 
(20 mg, 0.15 mmol), and 0.5 mL of AcOH was added. The mixture was stirred and heated 
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to reflux for 5 hrs. Solvents were dried under vacuum and the crude yellow solid was 
purified by column chromatography. Yield: 42-47 %. 
4a-13C Riboflavin: 1H NMR (400 MHz, CD3OD):  2.23 (s, 3H), 2.34 (s, 3H), 3.73-3.97 
(m, 4H), 4.23-4.37 (m, 2H) 4.48 (m, 1H), 7.36 (s, 1H), 7.39 (s, 1H) ppm. 13C NMR (100 
MHz, DMSO-d6):  137.59 ppm (13C enriched C). 
2-13C Riboflavin: 1H NMR (400 MHz, CD3OD 2.23 (s, 3H), 2.34 (s, 3H), 3.73-3.97 
(m, 4H), 4.23-4.37 (m, 2H) 4.48 (m, 1H), 7.36 (s, 1H), 7.39 (s, 1H) ppm. 13C NMR (100 
MHz, DMSO-d6):  159.60 ppm (13C enriched C). 
4,10a-13C Riboflavin: 1H NMR (400 MHz, CD3OD 2.23 (s, 3H), 2.34 (s, 3H), 3.73-
3.97 (m, 4H), 4.23-4.37 (m, 2H) 4.48 (m, 1H), 7.36 (s, 1H), 7.39 (s, 1H) ppm. 13C NMR 
(100 MHz, DMSO-d6):  151.30, 162.95 ppm (13C enriched C). 
Synthesis of FMN (11): Riboflavin (55) was converted to FMN (11) enzymatically 
using RibK from Methanocaldococcus jannaschii. Riboflavin was incubated for 30 mins 
at 70 oC with 5 mM CTP, 20 mM MgCl2 and RibK in 100 mM potassium phosphate buffer, 
pH 7.5. The reaction mixture was passed through a 10kDa cut-off filter and purified by 
reverse phase high performance liquid chromatography.   
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2.4.16 Synthesis of N-[(3-Oxo-3,4-dihydroquinoxalin-2-yl)carbonyl]urea (Alloxan-
oPDA adduct, 40)41 
 The synthetic scheme for the alloxan-oPDA adduct is shown in Figure 24. 
 
 
 
 
 
 
Procedure 
            Synthesis of N-[(3-Oxo-3,4-dihydroquinoxalin-2-yl)carbonyl]urea (Alloxan-
oPDA adduct (40): o-Phenylenediamine, 39 (108 mg, 1.0 equiv.) was dissolved in 10 mL 
of water and was then added to the aqueous solution of alloxan, 29 (160 mg, 1.0 equiv. in 
10 mL). A yellow precipitate was immediately formed. The reaction mixture was heated 
at 80 oC for an hour and was then filtered followed by washing with hot water to yield the 
final compound. Yield: 70%, ESI-MS m/z 233.1 (M+H). 1H NMR (400 MHz, 
CDCl3/CF3COOH):  7.1 (br, 1H), 7.54 (d, 1H), 7.68 (t, 1H), 7.91 (t, 1H), 8.14 (d, 1H), 
8.65 (br, 1H) ppm. 13C NMR (100 MHz, CDCl3/CF3COOH):  116.7, 128.1, 131.2, 132.0, 
133.3, 137.1, 139.9, 156.4, 157.2, 163.0 ppm. 
 
 
 
Figure 24. Scheme for the synthesis of alloxan-oPDA adduct (40) 
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CHAPTER III 
TRAPPING OF KEY REACTION INTERMEDIATES IN THE BLUB CATALYZED 
DIMETHYLBENZIMIDAZOLE FORMATION  
 
3.1 Introduction 
 In the last chapter, we have successfully identified alloxan as the product derived 
from the third ring of FMN. Molecular oxygen and water have been shown to be the two 
sources of oxygen atom incorporation in the alloxan. Based on our observations, a 
mechanism has been proposed which is consistent with all our experimental data. 
In a complex multi-step reaction, it is highly likely that some of the reactive 
intermediates may be trapped in the form of shunt products. Thus, in pursuit of the 
intermediates proposed in our mechanistic hypothesis, we looked for the formation of 
shunt products in the BluB catalyzed reaction. Several new products were seen to be 
formed only in case of full reaction in the HPLC and LC-MS analysis of the enzymatic 
reactions. All these new products were formed on carrying out the reactions with wild type 
BluB using the native substrate FMN. 
 
3.2 Results and Discussion 
3.2.1 Identification of the shunt product 56 
 BluB catalyzed reactions were carried out and analyzed in the HPLC and LC-MS. 
A new peak was seen to be formed only in case of full reaction at 320 nm in the HPLC 
chromatogram (Figure 25A). LCMS analysis of the new compound showed that the new 
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product has a mass of 232 Da (Figure 26). Based on the mass and MS-MS fragmentation 
pattern (Figure 27), we proposed 56 as the possible structure of the new compound. The 
proposed structure for the new compound was confirmed by synthesizing a standard and 
carrying out a coelution experiment (Figure 25B)44,45. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Identification of the shunt product 56. (A) HPLC chromatogram showing the formation of shunt 
product 56 (B) Coelution study for the formation of 56 
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Figure 26. LC-MS analysis of the formation of the shunt product 56. (A) Extracted Ion Chromatogram 
(EIC) at m/z 231.0887 showing the formation of 56 only in case of full reaction (Red trace) (B) ESI-MS of 
56 in the negative mode  
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3.2.2 Labeling pattern for the shunt product 56 
Labeling studies were done to figure out the origin of various atoms in the shunt 
product 56. On carrying out the reaction with FMN labeled as 13C at the C1' of the ribose 
sugar chain, no increment in mass was observed for the new product indicating that the 
carbon at C1' is not incorporated (Figure 28A & B). Only one of the two carbons labeled 
at 4 and 10a positions was seen to be incorporated as a 1Da increase in mass was observed 
(Figure 28C & D). Both the carbons labeled at 2 (Figure 28E & F) and 4a (Figure 28G & 
H) positions were incorporated and in both the cases a 1Da increment was seen in the mass 
of the new shunt product (56).  
 
 
 
 
 
145.0757 
 
118.0646 
 
173.0705 
 
Figure 27. MS-MS fragmentation pattern of 56 in the positive mode 
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Figure 28. LC-MS analysis of the labeling pattern for the shunt product 56. (A) EIC at m/z 231.0887 
showing  that the carbon at C1'  position of the ribose sugar chain of FMN is not incorporated in 56 when 
FMN labeled as 13C at C1'  position of ribose is used as substrate (B) ESI-MS of 56 formed on using FMN 
labeled as 13C at C1'  position of ribose as substrate in the negative mode (C) EIC at m/z 232.0921 showing 
that only one of the two carbons at 4,10a positions of FMN is incorporated in 56 when 4,10a-13C FMN is 
used as substrate (D) ESI-MS of 56 formed on using 4,10a-13C FMN as substrate in the negative mode (E) 
EIC at m/z 232.0921 showing that the carbon at 2 position of FMN is incorporated in 56 when 2-13C FMN 
is used as substrate (F) ESI-MS of 56 formed on using 2-13C FMN as substrate in the negative mode (G) 
EIC at m/z 232.0921 showing that the carbon at 4a position of FMN is incorporated in 56 when 4a-13C FMN 
is used as substrate (H) ESI-MS of 56 formed on using 4a-13C FMN as substrate in the negative mode 
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Figure 28. Continued 
 
 
 
 
 
 
 
 
 
 
Substrate Mass obtained 
FMN 231.1 
C1'  (Ribose) 13C FMN 231.1 
4,10a-13C FMN 232.1 
2-13C FMN 232.1 
4a-13C FMN 232.1 
Table 1. Labeling study for the formation of shunt product 56 
16 18 20 22 24 26 Time [min]
0
2000
4000
6000
Intens.
FR BluB 2-13C FMN_1-D,1_01_22276.d: EIC 232.0916±0.01 -All MS No BluB 2-13C FMN_1-C,9_01_22275.d: EIC 232.0916±0.01 -All MS
E) 
1                 1                2                  2                2                2         Time ( i s)   
Intens. 
 
6000 
5000 
400  
3000 
200  
1000 
10000 
 
Full Reaction 
No BluB 
14 16 18 20 22 24 26 28 Time [min]
0
500
1000
1500
2000
2500
Intens.
FR BluB (4a-13C FMN)_1-C,6_01_22652.d: EIC 232.0916±0.01 -All MS No BluB (4a-13C FMN)_1-C,5_01_22651.d: EIC 232.0916±0.01 -All MS
G) 
1              1              1              20              2              2              2       Time ( i s)   
Intens. 
 
250  
 
200  
 
150  
 
100  
 
50  
 
10000 
Full Reaction 
No BluB 
H) 
232.0920 
F) 
232.0909 
 37 
 
Figure 30. Formation of shunt product 57 on carrying out reactions using dithionite as the reducing agent 
The results of the labeling studies for shunt product 56 have been summarized in Table 1. 
Based on all these results, we propose the labeling pattern for the shunt product 56 
to be as shown in figure 29. 
 
 
 
 
 
3.2.3 Identification of the shunt product 57  
On reducing the substrate FMN chemically, using sodium dithionite instead of the 
enzymatic system comprising NADH/Fre, led to the formation of a new peak observed at 
320 nm in the HPLC chromatogram (Figure 30). Based on the mass and fragmentation 
pattern, we assigned 57 to be the structure for the new peak formed (Figure 31).  
 
 
 
 
 
 
 
 
Figure 29. Labeling pattern for the shunt product 56 
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3.2.4 Labeling pattern for the shunt product 57 
Labeling studies were performed using 13C labeled FMN isotopologues to figure 
out the origin of various atoms in the shunt product 57. On carrying out the reaction with 
FMN labeled as 13C at the C1' of the ribose sugar chain, a 1Da increment in mass was 
observed for the new product indicating the carbon at C1' is incorporated (Figure 32A & 
B). Only one of the two carbons labeled at 4 and 10a positions was seen to be incorporated 
as a 1Da increase in mass was observed (Figure 32C & D). Both the carbons labeled at 2 
(Figure 32E & F) and 4a (Figure 32G & H) positions were incorporated as in both the 
cases a 1Da increment was observed. 
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Figure 31. LC-MS analysis of the formation of the shunt product 57. (A) Extracted Ion Chromatogram 
(EIC) at m/z 325.0612 showing the formation of 57 only in case of full reaction (Red trace) (B) ESI-MS of 
57 in the negative mode  
B) 
325.0618 
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Figure 32. LC-MS analysis of the labeling pattern of the shunt product 57. (A) EIC at m/z 326.0646 showing 
that the carbon at C1'  position of the ribose sugar chain of FMN is incorporated in 57 when FMN labeled 
as 13C at C1'  position of ribose is used as substrate (B) ESI-MS of 57 formed on using FMN labeled as 13C 
at C1'  position of ribose as substrate in the negative mode (C) EIC at m/z 326.0646 showing that only one 
of the two carbons at 4,10a positions of FMN is incorporated in 57 when 4,10a-13C FMN is used as substrate 
(D) ESI-MS of 57 formed on using 4,10a-13C FMN as substrate in the negative mode (E) EIC at m/z 
326.0646 showing that the carbon at 2 position of FMN is incorporated in 57 when 2-13C FMN is used as 
substrate (F) ESI-MS of 57 formed on using 2-13C FMN as substrate in the negative mode (G) EIC at m/z 
326.0646 showing that the carbon at 4a position of FMN is incorporated in 57 when 4a-13C FMN is used as 
substrate (H) ESI-MS of 57 formed on using 4a-13C FMN as substrate in the negative mode 
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Figure 32. Continued 
 
 
 
 
 
 
 
 
 
Substrate Mass obtained 
FMN 325.1 
C1' (Ribose)-13C FMN 326.1 
4,10a-13C FMN 326.1 
2-13C FMN 326.1 
4a-13C FMN 326.1 
Table 2. Summary of the labeling studies for the shunt product 57 
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The results of the labeling studies for shunt product 57 have been summarized in Table 2. 
Thus, based on the above results, the labeling pattern for the shunt product 57 is as 
shown in figure 33. 
 
 
 
 
 
 
3.2.5 Formation of the shunt product 57 in presence of sodium bisulfite 
The formation of the shunt product 57 was observed on carrying out BluB 
catalyzed reactions using dithionite as the reducing agent. The shunt product 57, thus, 
formed seems to be a dithionite adduct of one of the intermediates in our mechanistic 
proposal for DMB formation. Our hypothesis is that the reduction of flavin with dithionite 
forms bisulfite as a by-product which subsequently acts as a nucleophile and traps one of 
the reaction intermediates in the form of an adduct (57). To test this, BluB catalyzed 
reactions were carried out in presence of sodium bisulfite using NADH/Fre as the reducing 
agent instead of dithionite. We observed the formation of the same shunt product (57) as 
seen in case of reactions carried out using dithionite as the reducing agent (Figure 34). The 
formation of 57, however, was not observed in the absence of bisulfite. 
 
 
Figure 33. Labeling pattern for the shunt product 57 
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Formation of 57 was also confirmed by LC-MS analysis, wherein, the shunt 
product was only seen in the enzymatic reaction carried out in the presence of sodium 
bisulfite (Figure 35).  
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Figure 34. Formation of 57 in the BluB catalyzed reactions in the presence of sodium bisulfite 
Figure 35. LC-MS analysis of BluB catalyzed reactions in presence of sodium bisulfite. (A) Extracted Ion 
Chromatogram (EIC) at m/z 325.0612 showing the formation of the shunt product 57 only in case of full 
reaction carried out in presence of bisulfite (Red trace) (B) ESI-MS of 57 in the negative mode  
 
B) 
325.0617 
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Usually, bisulfite forms adduct through an attack from the sulfur center leading to 
a C-S bond. However, in the case of shunt product 57, MS-MS fragmentation pattern 
indicates the attack occurs through the oxygen atom forming a C-O linkage as the 
nucleophilic attack from the sulfur center may be hindered due to steric effect (Figure 36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.6 Identification of the shunt product 58 in the presence of sodium 
cyanoborohydride 
The results obtained indicate that the intermediate trapped by bisulfite may contain 
a reactive imine or carbonyl functional group as bisulfite is known to form stable adducts 
with compounds containing either an imine or a carbonyl moiety. To figure this out, we 
performed BluB reactions in the presence of sodium cyanoborohydride which can 
potentially reduce these functional groups. On carrying out reactions using 
cyanoborohydride, we observed the formation of a new peak (58) (Figure 37A) whose 
145.0768 
239.0487 
173.0714 
282.0546 
Figure 36. MS-MS fragmentation analysis of 57 in the negative mode 
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Figure 38. LC-MS analysis of BluB catalyzed reaction in presence of sodium cyanoborohydride. (A) 
Extracted Ion Chromatogram (EIC) at m/z 247.1190 showing the formation of the shunt product 58 only in 
case of full reaction carried out in presence of cyanoborohydride (Red trace) (B) ESI-MS of 58 in the positive 
mode (C) MS-MS fragmentation pattern of 58 in the positive mode 
structure was confirmed by coelution studies (Figure 37B) and LC-MS analysis (Figure 
38)46,47. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. BluB catalyzed reactions in presence of sodium cyanoborohydride. (A) HPLC Chromatogram 
showing the formation of the shunt product 58 (B) Coelution study for formation of product 58                       
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Figure 38. Continued 
 
These results confirm that the intermediate trapped contains an imine moiety which 
gets reduced in the presence of cyanoborohydride forming 58. This was further confirmed 
by using cyanoborodeuteride wherein a 1Da increment in mass was observed (Figure 39). 
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Figure 39. Deuterium incorporation studies in the shunt product 58. (A) EIC at m/z 248.1252 showing the 
incorporation of deuterium in 58 in presence of cyanoborodeuteride (B) ESI-MS of 58a in the positive mode 
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3.2.7 Labeling pattern for the shunt product 58 
Labeling studies were done to figure out the origin of various atoms in the shunt 
product 58. On carrying out the reaction with FMN labeled as 13C at the C1' of the ribose 
sugar chain, a 1Da increment in mass was observed indicating that the carbon at C1' is 
incorporated (Figure 40A & B). Only one of the two carbons labeled at 4 and 10a positions 
was seen to be incorporated as only a 1Da increase in mass was observed (Figure 40C & 
D). The carbon labeled at 2 position was also incorporated with a 1Da increment seen in 
the mass of the shunt product 58 (Figure 40E & F). 
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Figure 40. LC-MS analysis of the labelling pattern of the shunt product 58. (A) EIC at m/z 248.1223 
showing that the carbon at C1'  position of the ribose sugar chain of FMN is incorporated in 58 when FMN 
labeled as 13C at C1'  position of ribose is used as substrate (B) ESI-MS of 58 formed on using FMN labeled 
as 13C at C1'  position of ribose as substrate in the positive mode (C) EIC at m/z 248.1223 showing that only 
one of the two carbons at 4,10a positions of FMN is incorporated in 58 when 4,10a-13C FMN is used as 
substrate (D) ESI-MS of 58 formed on using 4,10a-13C FMN as substrate in the positive mode (E) EIC at 
m/z 248.1223 showing that the carbon at 2 position of FMN is incorporated in 58 when 2-13C FMN is used 
as substrate (F) ESI-MS of 58 formed on using 2-13C FMN as substrate in the positive mode  
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Figure 40. Continued 
 
 
 
 
 
 
 
 
Substrate Mass obtained 
FMN 247.1 
C1' (Ribose)-13C FMN 248.1 
4,10a-13C FMN 248.1 
2-13C FMN 248.1 
Table 3. Summary of the labeling studies for the shunt product 58 
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The summary of the labeling studies for the shunt product 58 is shown in Table 3. 
Thus, based on the above data, the labeling pattern for the shunt product 58 is as 
shown in Figure 41. 
 
 
 
 
 
 
 
3.2.8 Mechanistic proposal for the formation of the shunt products (56, 57 and 58) 
We have thus successfully identified and characterized three shunt products (56, 
57 and 58). Our hypothesis is that these products are formed by trapping the reaction 
intermediate 27 (in Figure 21) in our mechanistic proposal for DMB biosynthesis. All the 
three above-mentioned shunt products are pretty closely related to one another in terms of 
their structure and thus must be formed following a common mechanism by trapping the 
intermediate 27 using various nucleophiles as shown in Figure 42. 
We propose that the intermediate 27, formed by a C-C bond cleavage between the 
C1 'and C2' of the ribose sugar chain, can react with various nucleophiles such as water, 
bisulfite and hydride apart from undergoing the usual chemistry to form DMB. This is due 
to the presence of a highly reactive imine moiety in 27 which is quite susceptible to attack 
by nucleophiles. Intermediate 27 can thus react with nucleophiles forming species 59 
Figure 41. Labeling pattern for the shunt product 58 
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which can undergo similar chemistry to the alloxan/alloxanic acid rearrangement (Figure 
11) to form 60 which is then followed by ring closure to form 62. Addition of water to 
C10a triggers a ring contraction to give 64. This can be followed by a decarboxylation step 
to loss CO2 in a conjugated fashion forming 65 which can finally oxidize to yield the shunt 
product 67. When X is water, one can expect a loss of formaldehyde forming the product 
56, X being bisulfite will lead to compound 57 and on X being hydride product 58 will be 
formed.  
 
  
 
 
 
  
 
  
  
 
  
  
 
Figure 42. Mechanistic proposal for the formation of shunt products 56, 57 and 58 
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3.2.9 Identification of lumichrome based shunt products as further evidence for the 
intermediate 27 
Having successfully identified and characterized the three shunt products, we next 
explored the possibility for the formation of any cyclic lumichrome derived shunt products 
which can again arise from the same reaction intermediate 27 (in Figure 21). We were 
indeed successful in identifying three more shunt products. One of these newly identified 
shunt products is a bisulfite adduct of lumichrome (68) formed only in reactions carried 
out using dithionite as the reducing agent (Figure 43). 
 
 
 
 
 
 
 
 
 
 
3.2.10 Labeling pattern for the shunt product 68 
Labeling studies were done to figure out the origin of various atoms in the shunt 
product 68. Both the carbons labeled at 4 and 10a positions were seen to be incorporated 
as a 2Da increase in mass was observed (Figure 44A & B). The carbons labeled at 2 (Figure 
A) 
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Figure 43. LC-MS analysis of the formation of the shunt product 68. (A) Extracted Ion Chromatogram 
(EIC) at m/z 335.0456 showing the formation of 68 only in case of full reaction (Red trace) (B) ESI-MS of 
68 in the negative mode 
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335.0460 
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44C & D) as well as 4a (Figure 44E & F) positions were also incorporated with a 1Da 
increment seen in the mass of the shunt product 68 in both the cases. 
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Figure 44. LC-MS analysis of the labelling pattern of the shunt product 68. (A) EIC at m/z 337.0523 showing 
that both the carbons at 4,10a positions of FMN are incorporated in 68 when 4,10a-13C FMN is used as 
substrate (B) ESI-MS of 68 formed on using 4,10a-13C FMN as substrate in the negative mode (C) EIC at 
m/z 336.0489 showing that the carbon at 2 position of FMN is incorporated in 68 when 2-13C FMN is used 
as substrate (D) ESI-MS of 68 formed on using 2-13C FMN as substrate in the negative mode (E) EIC at m/z 
336.0489 showing that the carbon at 4a position of FMN is incorporated in 68 when 4a-13C FMN is used as 
substrate (F) ESI-MS of 68 formed on using 4a-13C FMN as substrate in the negative mode 
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Figure 44. Continued 
 
 
The summary of the labeling studies for shunt product 68 is shown in Table 4.  
 
 
 
 
 
 
 
 
 
 
 
 
Substrate Mass obtained 
FMN 335.1 
4,10a-13C FMN 337.1 
2-13C FMN 336.1 
4a-13C FMN 336.1 
Table 4. Labeling study for the formation of shunt product 68 
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Figure 46. LC-MS analysis of the formation of the shunt product-lumiflavin (69). (A) EIC at m/z 257.1033 
showing the formation of lumiflavin (69) only in case of full reaction carried out in presence of 
cyanoborohydride (Red trace) (B) ESI-MS of 69 in the positive mode 
Thus, based on these results, the labeling pattern for the shunt product 68 is as 
shown in Figure 45. 
 
 
 
 
 
 
 
3.2.11 Formation of lumiflavin as a shunt product 
Lumiflavin (69) formation was observed on carrying out the BluB catalyzed 
reaction using cyanoborohydride (Figure 46). Formation of 69 was confirmed by coelution 
and deuterium incorporation studies (Figure 47). 
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Figure 45. Labeling pattern for the shunt product 68 
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 54 
 
Figure 47. Deuterium and coelution studies for lumiflavin formation. (A) EIC at m/z 258.1096 showing the 
incorporation of deuterium in lumiflavin in presence of cyanoborodeuteride (B) ESI-MS of 69a in the 
positive mode (C) Coelution data for the formation of lumiflavin (69) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.12 Formation of lumichrome as a shunt product 
Having identified bisulfite adduct of lumichrome (68) and lumiflavin (69) as shunt 
products in BluB catalyzed reactions, we investigated further to look for the formation of 
lumichrome itself in the full reaction. The native substrate FMN undergoes slight 
degradation forming lumichrome which cannot be avoided even after HPLC purification. 
So, we used 8-substituted FMN analogs (8-OH FMN and 8-NH2 FMN) for this purpose to 
explore the possibility of formation of any corresponding 8-substituted lumichrome (8-OH 
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B) 
Figure 48. HPLC analysis of the lumichrome formation. (A) HPLC chromatogram showing the formation 
of 8-NH2 lumichrome (70) (B) Coelution data for the formation of 70 
 
lumichrome and 8-NH2 lumichrome, 70). In both the cases, the lumichrome formation was 
seen only in case of full reaction (Figure 48A) which was confirmed by coelution studies 
(Figure 48B). 
 
 
 
 
 
 
 
 
 
 
3.2.13 Mechanistic proposal for the formation of lumichrome based shunt products 
Similar to the formation of 56, 57 and 58, we propose a common mechanism for 
the formation of the three shunt products 68, 69 and 70 as shown in Figure 49. We propose 
that these three products are also formed by trapping the intermediate 27 (in Figure 21) 
using different nucleophiles such as water, bisulfite and hydride leading to the formation 
of species 59 which can readily cyclize to form the final shunt product 71. 
 
 
 
A) 
 56 
 
 
 
When X is water, one can readily lose formaldehyde to form lumichrome, X being 
bisulfite will lead to the formation of 68 and finally when X is hydride one will observe 
the formation of lumiflavin (69).  
 
 
 
 
 
 
 
 
 
 
 
Figure 49. Mechanistic hypothesis for formation of 68, 69 and 70 
Figure 50. Summary of the formation of different shunt products 
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Thus, we have successfully trapped one of the key reaction intermediates (27) in 
the DMB formation in the form of six different shunt products using water, bisulfite and 
hydride as nucleophiles (Figure 50). In the case of water, we observed the formation of the 
shunt products 56 and lumichrome (72), in case of bisulfite products 57 and 68 are formed 
while in the presence of cyanoborohydride as the hydride donor formation of 58 and 
lumiflavin (69) is seen. 
The identification and characterization of these six shunt products, thus, provide 
evidence for the existence of the intermediate 27 in our mechanistic proposal. Trapping of 
27 also establishes the actual sequence of the release of the products in the DMB formation. 
The intermediate 27 still has the alloxan moiety attached to it and thus we can conclude 
that the release of the sugar (erythrose-4-phosphate, 14) occurs first followed by the 
formation of alloxan (29).  
 
3.2.14 Trapping of the intermediate 35 in the form of the shunt product 73 
In pursuit of the late intermediates proposed in our mechanistic hypothesis, we 
were able to identify the formation of a new shunt product seen only in full reaction at 320 
nm in HPLC chromatogram (Figure 51A). Based on the mass observed in the LC-MS 
analysis (Figure 52), we proposed 73 as the possible structure for the new compound which 
was further confirmed by synthesizing a standard and carrying out a coelution experiment 
(Figure 51B)41. 
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3.2.15 Mechanistic proposal for the formation of the shunt product 73 
Our proposal for the formation of 73 is that it arises from the reaction of alloxan 
(29) with the hydrolyzed product of intermediate 35 (in Figure 21) in our mechanistic 
hypothesis for DMB formation (Figure 53). The intermediate 35 formed undergoes 
Figure 51. Identification of the shunt product 73. (A) HPLC chromatogram for the formation of the shunt 
product 73 (B) Coelution study for 73 
B) 
259.0830 
Figure 52. LC-MS analysis of the formation of the shunt product 73. (A) EIC at m/z 259.0837 showing the 
formation of 73 only in case of full reaction (Red trace) (B) ESI-MS of 73 in the negative mode 
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cyclisation and oxidation to form the native product DMB. It can, however, also undergo 
hydrolysis to form 74 followed by loss of formaldehyde to give 4,5-Dimethyl-1,2-
phenylenediamine (75) which can further react with alloxan, 29 (already present in the 
reaction mixture as one of the products of DMB biosynthesis) forming shunt product 73. 
 
 
 
 
 
 
The identification of the shunt product 73, thus, proves the intermediacy of 35 in 
our hypothesis for the biosynthesis of DMB. It also helps us establish the sequence of 
events, wherein, alloxan is released first followed by the cyclisation step in DMB 
formation. 
 
3.3 Conclusion 
 We have successfully identified and characterized the formation of several shunt 
products during the biosynthesis of dimethylbenzimidazole.  
A key intermediate (27) in our mechanistic proposal has been successfully trapped 
in the form of six different shunt products using water, bisulfite and hydride as 
nucleophiles. Presence of the imine functionality in the intermediate 27 was confirmed by 
trapping it with bisulfite as well as reducing it with cyanoborohydride and deuterium 
Figure 53. Mechanistic proposal for the formation of 73 
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studies. Trapping of 27 also helps us establish the sequence of the release of the products 
during DMB formation, wherein, the C-C bond cleavage occurs first forming erythrose-4-
phosphate followed by the release of alloxan.  
Characterization of the shunt product 73 provides evidence for the intermediacy of 
35 in our mechanistic hypothesis. 
 
3.4 Experimental 
3.4.1 Over-expression and purification of FAD synthetase48 
The FAD synthetase gene, cloned in a pET24b vector with a C-terminal His-tag, 
was transformed into Escherichia coli BL21 (DE3) cell line. A 10 mL starter culture was 
grown at 37 oC containing 40 μg/mL kanamycin for 6 hrs. 1.5 liters of LB media was 
inoculated with this starter culture. The cells were grown at 37 oC with shaking till the 
OD600 reached 0.6. The protein expression was then induced by adding IPTG (final 
concentration 1 mM) and the culture was incubated at 15 oC for 15 hrs. The cells were then 
harvested by centrifugation and resuspended in 30 mL of binding buffer (50 mM KPi 
buffer containing 150 mM NaCl, 10mM imidazole, pH 7.8). The cells were lysed by 
sonication followed by centrifugation at 15000 rpm for 45 mins. The supernatant 
containing the soluble protein was loaded on a Ni-NTA affinity column (Histrap-GE 
Healthcare) and was then washed with 50 mL of wash buffer (50 mM KPi buffer 
containing 150 mM NaCl, 20mM imidazole, pH 7.8). The protein was eluted with the 
elution buffer (100 mM KPi buffer containing 100 mM NaCl, 250 mM imidazole, pH 7.8). 
The eluted protein fractions were pooled and concentrated using 10kDa Amicon 
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ultracentrifugal filters to a final volume of 3 mL. The concentrated protein solution was 
buffer exchanged into 100 mM KPi buffer containing 150 mM NaCl and 15% glycerol, 
pH 7.8 using an Econo-Pac 10DG desalting column.  
 
3.4.2 Reconstitution of BluB using dithionite as reducing system 
 BluB enzymatic reactions were performed in 100 mM phosphate buffer, pH 7.5 
containing BluB (100 μM), FMN (500 μM) and dithionite. The enzymatic reactions were 
incubated at room temperature for 4 hrs. The protein was removed by heat denaturation 
and the reaction mixture was analyzed by HPLC and LC-MS. 
 
3.4.3 BluB reactions in the presence of sodium bisulfite 
BluB enzymatic reactions were performed in 100 mM phosphate buffer, pH 7.5 
containing BluB (100 μM), FMN (500 μM), NADH (2 mM), E. coli flavin reductase, Fre 
(200 nM) and 10 mM sodium bisulfite. The enzymatic reactions were incubated at room 
temperature for 4 hrs. The protein was removed by heat denaturation and the reaction 
mixture was analyzed by HPLC and LC-MS. 
 
3.4.4 BluB reactions in the presence of sodium cyanoborohydride 
BluB enzymatic reactions were performed in 100 mM phosphate buffer, pH 7.5 
containing BluB (100 μM), FMN (500 μM), NADH (2 mM), E. coli flavin reductase, Fre 
(200 nM) and 10 mM sodium cyanoborohydride. The enzymatic reactions were incubated 
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at room temperature for 4 hrs. The protein was removed by heat denaturation and the 
reaction mixture was analyzed by HPLC and LC-MS. 
 
3.4.5 Synthesis of the shunt product 56 
 The synthetic scheme for the shunt product 56 is shown in the Figure 5444,45. 
 
 
 
 
 
 
 
 
 
Procedure 
            Synthesis of 5,6-Dimethyl-2-hydroxymethylbenzimidazole (77): 4,5-Dimethyl-o-
phenylenediamine, 75 (136 mg, 1.0 equiv.), glycolic acid, 76 (114 mg, 1.5 equiv.), 4(N) 
HCl (10 mL) and water (10 mL) were all taken in a round bottom flask and the mixture 
was refluxed overnight. After cooling, the solution was neutralized slowly with NaOH and 
the precipitate thus formed was collected by filtration. Yield: 80%, ESI-MS m/z 177.1 
(M+H). 1H NMR (400 MHz, CD3OD):  2.32 (s, 6H), 4.77 (s, 2H), 7.27 (s, 2H) ppm. 13C 
NMR (100 MHz, CD3OD):  20.3, 59.0, 115.8, 132.3, 138.0, 155.1 ppm. 
Figure 54. Scheme for the synthesis of 56 
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 Synthesis of 5,6-Dimethylbenzimidazole-2-carboxylic acid (78): Compound 5,6-
Dimethyl-2-hydroxymethylbenzimidazole, 77 (176 mg, 1 equiv.) and Na2CO3 (1.06 g, 10 
equiv.) were added to 10 mL of boiling water followed by the addition of potassium 
permanganate (237 mg, 1.5 equiv) in small portions. The mixture was refluxed overnight. 
The hot solution was filtered and the precipitate of MnO2 was washed with hot water. The 
filtrate was cooled and carefully neutralized with hydrochloric acid. The precipitated 5,6-
Dimethylbenzimidazole-2-carboxylic acid (78) was collected by filtration. LC-MS m/z 
191.1 (M+H). 
 Synthesis of N-Carbamoyl-5,6-dimethylbenzimidazole-2-carboxamide (56): 5,6-
Dimethylbenzimidazole-2-carboxylic acid, 78 (1 equiv.), BOP (1.2 equiv.), cyanamide 
(1.5 equiv) and DIEA (3 equiv.) were dissolved in DMF (5 mL) and the reaction mixture 
was stirred at rt for 16 hrs. 12(N) HCl (2 mL) was added to the reaction mixture and it was 
further stirred at rt for another 16 hrs. The desired compound thus formed was purified by 
reverse phase high performance liquid chromatography. LC-MS m/z 233.1 (M+H). 1H 
NMR (400 MHz, DMSO-d6/CD3OD):  2.33 (s, 6H), 7.45 (s, 2H) ppm. 13C NMR (100 
MHz, DMSO-d6/CD3OD):  20.0, 116.1, 134.0, 136.6, 142.4, 152.3, 158.3 ppm. 
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3.4.6 Synthesis of the shunt product 58 
 The synthetic scheme for the shunt product 58 is shown in the Figure 5546,47. 
. 
  
  
 
 
 
 
Procedure 
Synthesis of N-Methyl-4,5-dimethyl-2-nitrobenzenamine (80): Aqueous 
formaldehyde (10 mL, 37%) was added slowly in a dropwise manner to a mixture of 4,5-
Dimethyl-2-nitroaniline, 79 (1 g) and conc. H2SO4 (10 mL). The mixture was then heated 
for 3 hrs at 65 oC, cooled and poured into ice water (500 mL). The solid was collected by 
filtration and was then dissolved in ethyl acetate. The solution was then washed with 
saturated NaHCO3 and was dried using Na2SO4. The resulting solution was filtered and 
evaporated to give the desired compound in the form of a red-orange solid. Yield: 90%, 
LC-MS m/z 181.1 (M+H). 1H NMR (400 MHz, CDCl3):  2.16 (s, 3H), 2.26 (s, 3H), 2.98 
(s, 3H), 6.59 (s, 1H), 7.90 (s, 1H) ppm. 13C NMR (100 MHz, CDCl3):  18.5, 20.7, 29.7, 
113.7, 124.3, 126.4, 145.0, 147.3 ppm. 
Figure 55. Scheme for the synthesis of 58 
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Synthesis of N-Methyl-4,5-dimethylbenzene-1,2-diamine (81): Catalytic 
reduction of N-Methyl-4,5-dimethyl-2-nitrobenzenamine, 80 (1 equiv.) was carried out 
using 10% Pd/C (4% Pd w/w) and NaBH4 (3 equiv.) in MeOH under argon at rt. After 40 
mins, the reaction mixture was filtered through celite and washed with MeOH. The filtrate 
was evaporated to give the desired compound. Yield: 90%, LC-MS m/z 151.1 (M+H). 1H 
NMR (400 MHz, CD3OD):  2.22 (s, 3H), 2.26 (s, 3H), 2.91 (s, 3H), 6.53 (s, 1H), 6.65 (s, 
1H) ppm. 13C NMR (100 MHz, CD3OD):  18.9, 19.3, 31.7, 114.4, 119.3, 126.7, 128.4, 
133.2, 137.5 ppm. 
Synthesis of 1,5,6-Trimethyl-2-hydroxymethylbenzimidazole (82): N-Methyl-4,5-
dimethylbenzene-1,2-diamine, 81 (150 mg, 1.0 equiv.), glycolic acid, 76 (114 mg, 1.5 
equiv.), 4(N) HCl (10 mL) and water (10 mL) were all taken in a round bottom flask and 
the mixture was refluxed overnight. After cooling, the solution was neutralized slowly with 
NaOH and the precipitate thus formed was collected by filtration. Yield: 80%, LC-MS m/z 
191.1 (M+H). 1H NMR (400 MHz, DMSO-d6):  2.28 (s, 3H), 2.32 (s, 3H), 3.75 (s, 3H), 
4.66 (s, 2H), 7.25 (s, 1H), 7.33 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6):  19.8, 20.0, 
29.7, 56.3, 109.8, 119.0, 129.4, 130.5, 134.6, 140.3, 153.0 ppm. 
Synthesis of 1,5,6-Trimethylbenzimidazole-2-carboxylic acid (83): Compound 
1,5,6-trimethyl-2-hydroxymethylbenzimidazole, 82 (190 mg, 1 equiv.) and Na2CO3 (1.06 
g, 10 equiv.) were added to 10 mL of boiling water followed by the addition of potassium 
permanganate (237 mg, 1.5 equiv) in small portions. The mixture was refluxed overnight. 
The hot solution was filtered and the precipitate of MnO2 was washed with hot water. The 
filtrate was cooled and carefully neutralized with hydrochloric acid. The precipitated N-
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Methyl-5,6-dimethylbenzimidazole-2-carboxylic acid (83) was collected by filtration. LC-
MS m/z 203.1 (M-H). 1H NMR (400 MHz, DMSO-d6):  2.29 (s, 3H), 2.33 (s, 3H), 4.05 
(s, 3H), 7.25 (s, 1H), 7.37 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6):  19.9, 20.1, 
31.4, 110.5, 119.5, 129.9, 131.2, 134.6, 139.3, 150.2, 162.3 ppm. 
            Synthesis of N-Carbamoyl-1,5,6-trimethylbenzimidazole-2-carboxamide (58): 
Compound 1,5,6-Trimethylbenzimidazole-2-carboxylic acid, 83 (1 equiv.), BOP (1.2 
equiv.), cyanamide (1.5 equiv) and DIEA (3 equiv.) were dissolved in DMF/MeOH (5 mL) 
and the reaction mixture was stirred at rt for 16 hrs. 12(N) HCl (2 mL) was added to the 
reaction mixture and it was further stirred at rt for another 16 hrs. The desired compound 
thus formed was purified by reverse phase high performance liquid chromatography. LC-
MS m/z 247.1 (M+H). 1H NMR (400 MHz, CD3OD):  2.39 (s, 3H), 2.44 (s, 3H), 4.16 (s, 
3H), 7.39 (s, 1H), 7.53 (s, 1H) ppm. 
 
 
 
 
 
 
 
 
 
 
 67 
 
3.4.7 Synthesis of 13C labeled FMN (Labeled at C1' position of ribose)49,50 
The synthetic scheme for 11d is shown in Figure 56. 
 
 
 
 
  
  
 
 
 
 
 
Procedure 
            Synthesis of 2-(Boc)amino-4,5-dimethylaniline (84): 4,5-Dimethylbenzene-1,2-
diamine, 75 (272 mg, 1 equiv.), Boc2O (218, 0.5 equiv.) and NaHCO3 (84 mg, 1 equiv.) 
were dissolved in 1:1 water-dioxane mixture (25 mL). The reaction mixture was stirred at 
rt for 5 hrs. The mixture was then diluted with water (30 mL) and extracted with DCM. 
The organic phase was then washed with saturated NaHCO3 solution followed by brine, 
dried over Na2SO4 and was concentrated. The residue was purified by silica gel column 
chromatography using chloroform/methanol. Yield: 90%. 1H NMR (400 MHz, CD3OD): 
Figure 56. Scheme for the synthesis of 11d 
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 1.49 (s, 9H), 2.11 (s, 3H), 2.13 (s, 3H), 6.61 (s, 1H), 6.87 (s, 1H) ppm. 13C NMR (100 
MHz, CD3OD):  18.8, 19.3, 28.7, 80.8, 119.9, 123.5, 127.9, 135.5, 140.0, 156.7 ppm. 
Synthesis of 85: Boc-protected aniline, 84 (1 equiv.), D-[13C1] ribose (3.0 equiv.) 
and sodium cyanoborohydride (2.0 equiv.) were dissolved in anhydrous MeOH (15 mL). 
The mixture was refluxed at 80 oC for 2 days under argon atmosphere. Then the solvent 
was removed under reduced pressure and excess NaBH3CN was quenched using 1M HCl. 
The resulting mixture was neutralized using saturated NaHCO3 solution and concentrated 
under reduced pressure. The residue was purified by silica gel column chromatography 
using chloroform/methanol. Yield: 80%, ESI-MS m/z 372.2 (M+H). 1H NMR (400 MHz, 
CD3OD):  1.44 (s, 9H), 2.07 (s, 3H), 2.13 (s, 3H), 3.26 (m, 1H), 3.58 (m, 3H), 3.71 (m, 
2H), 3.88 (m, 1H), 6.56 (s, 1H), 6.85 (s, 1H) ppm.   
            Synthesis of 86: Boc-protected riboaniline, 85 (100 mg) was stirred in 4(N) 
HCl/dioxane mixture (5 mL) for 4 hrs. The solvent was removed under reduced pressure 
and the remaining mixture was diluted with water followed by extraction with ether. The 
aqueous layer was concentrated to yield the desired product. Yield: 90%. 1H NMR (400 
MHz, CD3OD):  2.31 (s, 3H), 2.32 (s, 3H), 3.52 (m, 1H), 3.86 (m, 5H), 4.11 (br, 1H), 
7.44 (s, 1H), 7.52 (s, 1H) ppm.   
Synthesis of 55d: Compound 86 (1 equiv.), alloxan monohydrate (3 equiv.) and 
boric acid (2 equiv.) were dissolved in 20 mL of acetic acid. The reaction mixture was 
stirred overnight under argon atmosphere and the desired 13C labeled riboflavin (55d) was 
purified by reverse phase high performance liquid chromatography. LC-MS m/z 378.1 
(M+H) (Figure 57). 
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Synthesis of 11d: Compound 55d was converted to 13C labeled FMN enzymatically 
using RibK from Methanocaldococcus jannaschii. 55d was incubated for 30 mins at 70 oC 
with 5 mM CTP, 20 mM MgCl2 and RibK in 100 mM potassium phosphate buffer, pH 7.5. 
The reaction mixture was passed through a 10kDa cut-off filter and purified by reverse 
phase high performance liquid chromatography. LC-MS m/z 458.1 (M+H) (Figure 58). 
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Figure 58. LCMS analysis of the synthesized 13C labeled FMN 11d (Labeled at C1' position of ribose). (A) 
EIC at 458.1152 showing the formation of 13C labeled FMN (B) ESI-MS of 11d in the positive mode  
 
Figure 57. LCMS analysis of the synthesized 13C labeled riboflavin 55d (Labeled at C1' position of ribose). 
(A) EIC at m/z 378.1489 showing the formation of 13C labeled riboflavin (B) ESI-MS of 55d in the positive 
mode 
 
11d 
55d 
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3.4.8 Synthesis of 8-NH2 FMN (93)
51,52 
 The synthetic scheme for 8-NH2 FMN (93) is shown in Figure 59.  
 
 
 
 
 
 
 
 
Procedure 
Synthesis of 5-((4-Methyl-3-nitrophenyl)amino)pentane-1,2,3,4-tetraol (88): 
Methyl-3-nitrophenylamine, 87 (152 mg, 1.0 equiv.), D-ribose (450 mg, 3.0 equiv.) and 
sodium cyanoborohydride (126 mg, 2.0 equiv.) were dissolved in anhydrous MeOH (15 
mL). The mixture was refluxed at 80 oC for 2 days under argon atmosphere. Then the 
solvent was removed under reduced pressure and excess NaBH3CN was quenched using 
1M HCl. The resulting mixture was neutralized using saturated NaHCO3 solution and 
concentrated under reduced pressure. The residue was purified by silica gel column 
chromatography using chloroform/methanol (98:2 to 80:20). Yield: 50%, LC-MS m/z 
285.1 (M-H). 1H NMR (400 MHz, CD3OD):  2.36 (s, 3H), 3.15-3.21 (m, 1H), 3.45 (dd, 
Figure 59. Scheme for the synthesis of 8-NH2 FMN (93) 
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1H), 3.61-3.67 (m, 2H), 3.72-3.80 (m, 2H), 3.89-3.94 (m, 1H), 6.87 (dd, 1H), 7.08 (d, 1H), 
7.21 (d, 1H) ppm.  13C NMR (100 MHz, CD3OD):  19.2, 47.1, 64.4, 72.1, 74.1, 74.4, 
108.3, 119.0, 121.2, 133.9, 149.3, 151.0 ppm. 
Synthesis of 5-((3-Amino-4-methylphenyl)amino)pentane-1,2,3,4-tetraol (89): 
Compound 88 (100 mg) was dissolved in 50 mL MeOH and passed through a Thalesnano 
H-cube hydrogenator with 10% Pd/C catalyst at 40 oC and 1 bar hydrogen gas pressure at 
a flow rate of 1.0 mL/min. The solution was then concentrated under reduced pressure and 
the resulting compound 89 was used for the next coupling step without further purification. 
Yield: 90%, LC-MS m/z 255.1 (M-H). 1H NMR (400 MHz, CD3OD):  2.02 (s, 3H), 3.39 
(dd, 1H), 3.44-3.51 (m, 1H), 3.61-3.68 (m, 2H), 3.74-3.80 (m, 2H), 3.88-3.92 (m, 1H), 
6.09 (dd, 1H), 6.16 (d, 1H), 6.75 (d, 1H) ppm. 13C NMR (100 MHz, CD3OD):  16.5, 48.1, 
64.4, 72.1, 74.1, 74.8, 102.7, 106.2, 114.1, 131.7, 146.6, 148.9 ppm. 
Synthesis of 8-Aminoriboflavintetraacetate (90): To a solution of 89 in 15 mL of 
water, violuric acid monohydrate (175 mg) and boric acid (62 mg) were added. The 
mixture was refluxed at 105 oC for 12 hours and was then concentrated under reduced 
pressure. The crude product was dissolved in 8 mL of pyridine. 1 mL of acetic anhydride 
was added to the mixture and was stirred at RT for 6 hrs. The solvent was then removed 
under reduced pressure with toluene. The residue was purified by silica gel column 
chromatography using chloroform/methanol (95:5 to 80:20). LC-MS m/z 544.2 (M-H). 1H 
NMR (400 MHz, CD3OD):  1.98 (s, 3H), 2.01 (s, 3H), 2.14 (s, 3H), 2.18 (s, 3H), 2.28 (s, 
3H), 4.24 (dd, 2H), 4.48 (dd, 1H), 5.37-5.41 (m, 2H), 5.48 (t, 1H), 5.63-5.67 (m, 1H), 6.81 
(s, 1H), 7.61 (s, 1H) ppm. 13C NMR (100 MHz, CD3OD):  17.1, 20.4, 20.6, 20.7, 20.9, 
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45.9, 62.9, 70.4, 71.0, 72.0, 96.0, 127.8, 127.9, 132.9, 134.8, 137.4, 152.4, 158.3, 158.7, 
163.4, 171.4, 171.6, 171.9, 172.4 ppm. 
Synthesis of 8-Aminoriboflavin (91): Compound 90 was converted to compound 
91 by overnight stirring in ammonia (7N in methanol). LC-MS m/z 376.1 (M-H) (Figure 
60A and B). 
Synthesis of 8-Aminoflavinadeninedinucleotide (92): Compound 91 was 
converted to 8-NH2 FAD (92) enzymatically using FAD synthetase enzyme from 
Corynebacterium ammoniagenes. 8-NH2 riboflavin (91) was incubated overnight at 37 
oC 
with 5 mM ATP, 20 mM MgCl2 and FAD synthetase in 100 mM potassium phosphate 
buffer, pH 7.5. The reaction mixture was passed through a 10kDa cut-off filter and purified 
by reverse phase high performance liquid chromatography. LC-MS m/z 785.1 (M-H) 
(Figure 60 C and D). 
Synthesis of 8-Aminoflavinmononucleotide (93): 8-NH2 FAD (92) purified by 
HPLC was incubated overnight at 37 oC with 2-3 mg of phosphodiesterase I from Crotalus 
atrox (Western Diamondback Rattlesnake) in 10 mL of 100 mM potassium phosphate 
buffer, pH 7.5. The reaction mixture was passed through a 10kDa cut-off filter and then 
purified by reverse phase high performance liquid chromatography to yield the final 
compound 8-NH2 FMN (93). LC-MS m/z 456.1 (M-H) (Figure 60E and F). 
1H NMR (400 
MHz, CD3OD):  2.18 (s, 3H), 3.91-3.94 (m, 1H), 3.99-4.03 (m, 2H), 4.05-4.10 (m, 1H), 
4.29-4.31 (m, 1H), 4.40 (d, 1H), 4.75-4.82 (m, 1H), 6.66 (s, 1H), 7.34 (s, 1H). 13C NMR 
(100 MHz, CD3OD):  16.4, 47.2, 66.1, 69.1, 71.2, 71.3, 72.8, 95.1, 124.3, 128.9, 132.6, 
132.7, 136.2, 150.4, 157.3, 158.1, 162.5 ppm. 
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Figure 60. HPLC and LC-MS analysis of the synthesized 8-NH2 FMN (93). (A) UV chromatogram at 450 
nm showing the formation of 8-NH2 Riboflavin (B) ESI-MS of 91 in the negative mode (C) UV 
chromatogram at 450 nm showing the formation of 8-NH2 FAD (D) ESI-MS of 92 in the negative mode (E) 
UV chromatogram at 450 nm showing the formation of 8-NH2 FMN (F) ESI-MS of 93 in the negative mode 
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3.4.9 Synthesis of 8-NH2 lumichrome (70) 
 The synthetic scheme for 8-NH2 lumichrome (70) is shown in Figure 61. 
 
 
 
 
Procedure 
Synthesis of 4-Methylbenzene-1,3-diamine (94): 4-Methyl-3-nitroaniline, 87 (100 
mg) was dissolved in 50 mL MeOH and passed through a Thalesnano H-cube 
hydrogenator with 10% Pd/C catalyst at 40 oC and 1 bar hydrogen gas pressure at a flow 
rate of 1.0 mL/min. The solution was then concentrated under reduced pressure and the 
resulting compound 94 was used for the next coupling step without further purification. 
Yield: 90%. 1H NMR (400 MHz, CD3OD):  2.03 (s, 3H), 6.09 (dd, 1H), 6.17 (d, 1H), 
6.72 (d, 1H) ppm. 13C NMR (100 MHz, CD3OD):  16.6, 104.7, 108.1, 114.9, 131.7, 146.7, 
146.9 ppm. 
Synthesis of 8-Aminolumichrome (70): To a solution of 4-Methylbenzene-1,3-
diamine, 94 (122 mg, 1 equiv.) in 15 mL of water, violuric acid monohydrate (175 mg, 1 
equiv.) and boric acid (62 mg, 1 equiv.) were added. The mixture was refluxed at 105 oC 
for 12 hours and was then concentrated under reduced pressure and purified. Yield: 40%. 
Figure 61. Scheme for the synthesis of 8-NH2 lumichrome (70) 
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1H NMR (400 MHz, DMSO-d6):  2.28 (s, 3H), 6.51 (s, 2H), 6.78 (s, 1H), 7.65 (s, 1H), 
11.33 (s, 1H), 11.46 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6):  17.6, 101.9, 123.6, 
129.5, 130.0, 134.6, 144.7, 146.7, 150.0, 153.3, 160.8 ppm. 
 
3.4.10 Synthesis of the shunt product 7341 
 The synthetic scheme for the shunt product 73 is shown in Figure 62. 
 
 
 
 
 
 
Procedure 
Synthesis of N-[(6,7-Dimethyl-3-oxo-3,4-dihydroquinoxalin-2-yl)carbonyl]urea 
(73): 4,5-Dimethyl-o-phenylenediamine, 75 (136 mg, 1.0 equiv.) was dissolved in 10 mL 
of water and was then added to the aqueous solution of alloxan, 29 (160 mg, 1.0 equiv. in 
10 mL). A precipitate was immediately formed. The reaction mixture was then heated at 
80 oC for an hour and was then filtered followed by washing with hot water to yield the 
final compound. Yield: 65%, LC-MS m/z 259.1 (M-H). 1H NMR (400 MHz, 
CDCl3/CF3COOH):  2.44 (s, 3H), 2.51 (s, 3H), 7.1 (br, 1H), 7.31 (s, 1H), 7.86 (s, 1H), 
8.64 (br, 1H) ppm. 13C NMR (100 MHz, CDCl3/CF3COOH):  19.6, 20.9, 116.4, 130.4, 
132.3, 137.8, 138.7, 149.9, 156.3, 157.0, 163.1 ppm. 
Figure 62. Scheme for the synthesis of the shunt product 73 
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CHAPTER IV 
ROLE OF THE ASPARTATE RESIDUE (ASP-32)  
 
4.1 Introduction 
 The active site of BluB consists of residues which are well conserved among the 
BluB orthologs but are found absent in oxidoreductases. Asp-32 is one such residue which 
has been shown to be very critical for the catalytic activity of BluB15. Mutation of Asp-32 
residue to alanine (Ala) or asparagine (Asn) results in loss of enzymatic activity. Typically, 
serine or arginine residue is seen to stabilize the N1 of FMN by H-bonding in the active 
sites of oxidoreductase, nitroreductase and IYD enzymes32. Interestingly, in BluB along 
with Arg-34, there is also Asp-32 which is in proximity to N1 of FMN as well as to the 
C1' of the ribityl chain of FMN30. Aspartate has never been seen at this position in the other 
enzymes which are structurally similar to BluB. In fact, the presence of aspartate at this 
position would be expected to destabilize the BluB-FMNH2 complex as the N1 of the 
reduced flavin often exists in the deprotonated form. Thus, the Asp-32 residue can be 
postulated to play an important role in stabilizing a reactive intermediate during the DMB 
formation in BluB. 
 
4.2 Results and Discussion 
4.2.1 Activity of D32N mutant and its comparison with the wild type enzyme 
 A closer look at the crystal structure of BluB revealed that the Asp-32 residue is 
well placed to undergo interaction with the C1' of the ribityl tail with the distance being 
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3.2 Å (Figure 63). To explore the role of the Asp-32 residue, it was mutated to asparagine 
and the corresponding D32N mutant was used for BluB enzymatic reactions.  
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
D32N mutant was found to be almost inactive towards the formation of the native 
product as only negligible amounts of DMB (13) formation was observed (Figure 64). 
Interestingly with the D32N mutant, shunt product 56 was seen to be formed in much 
greater amounts as compared to wild type BluB (Figure 65). 
Figure 63. Interaction of Asp 32 residue with C1' of the ribityl tail 
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B) A) 
Figure 64. HPLC analysis of the activity of D32N BluB mutant and its comparison with that of wild type 
BluB for the formation of DMB. (A) HPLC chromatogram at 280 nm showing the formation of DMB (13) 
using the D32N mutant (B) Comparison of activities of wild type BluB and D32N mutant towards DMB 
(13) formation 
Figure 65. HPLC analysis of the activity of D32N BluB mutant and its comparison with that of wild type 
BluB for the shunt product 56 formation. (A) HPLC chromatogram at 320 nm showing the formation of the 
shunt product 56 using the D32N mutant (B) Comparison of activities of wild type BluB and D32N mutant 
towards the formation of 56 
A) B) 
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           We next checked the activity of the D32N mutant for the formation of the other 
shunt products (57 and 58). Similar results were also obtained for the shunt products 57 
and 58 which were again seen to be formed in larger amounts compared to the wild type 
enzyme (Figure 66). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D) 
B) A) 
C) 
Figure 66. HPLC analysis of the activity of D32N BluB mutant and its comparison with that of wild type 
BluB. (A) HPLC chromatogram at 320 nm showing the formation of the shunt product 57 using the D32N 
mutant (B) Comparison of activities of wild type BluB and D32N mutant towards the formation of 57 (C) 
HPLC chromatogram at 320 nm showing the formation of the shunt product 58 using the D32N mutant (D) 
Comparison of activities of wild type BluB and D32N mutant towards the formation of 58 
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4.2.2 Revised mechanistic proposal for DMB biosynthesis 
The results obtained with the D32N mutant suggest that the residue Asp 32 plays 
a key role in stabilizing the key intermediate 27 (in Figure 21) during the formation of 
DMB. Based on this, our revised proposal for DMB formation is as shown in Figure 67. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67. Revised mechanistic proposal for DMB formation 
 81 
 
We propose that the residue Asp 32 forms an adduct (96) with intermediate 27, 
thereby, preventing it from getting hydrolyzed. The adduct 96 then undergoes hydrolysis 
to form 97 which subsequently undergoes C-N bond cleavage forming 98 with the release 
of alloxan (29). Flipping of the aryl ring is followed by elimination of Asp 32 to give the 
iminium ion 35. Cyclisation followed by oxidation leads to the formation of the final 
product DMB (13). Asp 32 thus plays an important role by protecting the reactive 
intermediate 27 in the form of an adduct. In the absence of this key residue, intermediate 
27 undergoes reactions with the various nucleophiles present leading to the formation of 
the shunt products exclusively as seen in case of D32N mutant. 
A closer look at the surface view of BluB (Figure 68) further helps us in explaining 
the formation of all the observed shunt products.  
 
  
  
  
  
 
 
 
 
 
 
 
Figure 68. Surface view showing the C1' (in red) of the ribityl chain of FMN being exposed to the solvent 
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The surface view structure shows that the substrate FMNH2 is deeply buried inside 
the active site pocket which is pretty much closed. Only a small opening is observed 
through which the substrate can have interaction with the external solvent. Looking 
closely, we observed that the C1' (shown in red color in Figure 68) of the ribityl tail is 
directly facing this opening. This explains the fact that once the intermediate 27 is formed 
having an imine moiety at the C1' position, it can readily undergo interaction with the 
external solvent and nucleophiles through this opening leading to the formation of the 
various shunt products. This observation, thus, helps us rationalize the different shunt 
products observed during the biosynthesis of dimethylbenzimidazole.  
 
4.3 Conclusion 
 In this chapter, we have demonstrated that the Asp 32 residue plays a key role 
during the DMB formation. It helps in the stabilization of the intermediate 27. Asp 32 
forms an adduct with 27 and thus shields it from getting hydrolyzed. Based on all these 
observations, a revised mechanism has been proposed for BluB catalyzed DMB 
biosynthesis.  Mutation of Asp 32 to asparagine (D32N mutant) leads to a loss in activity 
with regards to the DMB formation. However, greater amounts of the various shunt 
products are seen to be formed with the D32N mutant. Surface view of BluB further helps 
in explaining the formation of the different shunt products observed. 
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CHAPTER V 
STEREOCHEMISTRY OF PROTON ABSTRACTION FROM THE C1' POSITION OF 
THE RIBOSE SUGAR CHAIN OF FMN 
 
5.1 Introduction 
 Biosynthesis of DMB involves a novel transformation, wherein, the C1' of the sugar 
side chain in FMN is incorporated at the C2 position in the product, DMB20,21. One of the 
hydrogen is lost from the C1' of the sugar (highlighted in a blue circle) and only one is 
retained at the C2 position in DMB (Figure 69). 
 
 
 
 
   
 
Renz and co-workers have previously reported that the pro-S hydrogen of C1' of 
the sugar in FMN is retained in the DMB formed53. They concluded this based on their 
deuterium labeling studies wherein they observed 27% deuterium incorporation in the 
DMB formed on using flavin which contained 25% deuterium at 1' S position. However, 
on using the substrate flavin containing 75% deuterium at 1' S position, they only observed 
Figure 69. Overall scheme for the DMB formation 
 84 
 
46% deuterium incorporation in DMB which is pretty low. They attributed this low 
incorporation to the fact that a part of the deuterium may be incorporated in some other 
product derived from the substrate. Thus, the second result does not support the findings 
of the first based on which was concluded that the pro-S hydrogen at the C1' of FMN is 
retained in the final product, DMB. 
In our mechanistic hypothesis, we propose a final oxidation step in which the 
intermediate 30 (in Figure 67) is oxidized to form the final product, DMB. So, 
stereochemical studies were carried out to establish whether the proposed last step is an 
enzymatic or non-enzymatic process and whether there is any selectivity in the abstraction 
of one of the hydrogens from the C1' of the ribityl chain of FMN.  
 
5.2 Results and discussion 
 We synthesized deuterated forms of FMN, wherein, deuterium was incorporated at 
the C1' of the sugar side chain. Two forms of deuterated flavin were synthesized. One of 
the deuterated flavin synthesized had deuterium in the ratio of 3:1 in favor of R:S isomer 
at C1' position whereas the other form had it in the ratio of 1:3 in favor of R:S isomer at 
C1' position. These deuterated forms of FMN were used as substrates for BluB catalyzed 
reactions and the reaction mixture was analyzed by LC-MS to calculate the amount of 
deuterium incorporated in the DMB formed.  
On using the substrate containing 25% deuterium at 1' S position, we observed 
24.5% deuterium incorporation in the final product, DMB (Figure 70B). This data 
indicated that the pro-S hydrogen of the C1' of the sugar is retained in the DMB formed. 
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This was further confirmed by carrying out BluB reactions with the substrate containing 
75% deuterium at 1' S position. We observed 71% deuterium incorporation in DMB this 
time on using FMN containing 75% deuterium at 1' S position (Figure 70C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
145.0772 
146.0799 
A) 
1H DMB: 75.5%; 2H DMB: 24.5% 
145.0772 
146.0825 
B) C) 1H DMB: 29%; 2H DMB: 71% 
145.0771 
146.0837 
Figure 70. LC-MS analysis of the deuterium incorporation in DMB on using (A) Unlabeled FMN (B) 
Deuterated FMN (25% deuterium at 1' S position) (C) Deuterated FMN (75% deuterium at 1' S position) 
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The results of the deuterium incorporation studies have been summarised in Table 5. 
 
 
 
 
 
 
 
Based on both these above results, we can safely conclude that it is the pro-S 
hydrogen at the C1' of FMN which is retained in the DMB formed. Thus, we observe a 
selective abstraction of the pro-R hydrogen from the C1' position of the ribose side chain. 
These results thus help us infer that the proposed final oxidation step in DMB biosynthesis 
is indeed an enzymatic process. 
 
5.3 Conclusion 
 In this chapter, we have successfully demonstrated that there is a selectivity in the 
proton abstraction from the C1' position of the ribityl side chain. We have been able to 
show that the pro-R hydrogen is abstracted while the pro-S hydrogen is retained based on 
stereochemical studies. Thus, we have been able to establish that the final oxidation step 
involved in the DMB biosynthesis is enzyme catalyzed occurring in the active site of BluB. 
 
Substrate 
(Deuterated FMN) 
1H DMB 2H DMB 
75% R – 25% S 75.5% 24.5% 
25% R – 75% S 29.0% 71.0% 
Table 5. Summary of the deuterium incorporation studies in DMB 
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5.4 Experimental 
5.4.1 Synthesis of deuterated FMN (R:S::3:1)53,54 
 The synthetic scheme for 11e is shown in Figure 71. 
 
 
 
 
 
 
 
 
 
 
 
Procedure 
Synthesis of 2-(Boc)amino-4,5-dimethylaniline (84): Compound 84 was 
synthesized following the same procedure used during the synthesis of 13C labeled FMN 
11d (Labeled at C1' position of ribose). 
Synthesis of 85a: Boc-protected aniline, 84 (1 equiv.), D-ribose (3.0 equiv.) and 
sodium cyanoborodeuteride (2.0 equiv.) were dissolved in anhydrous MeOH (15 mL). The 
mixture was refluxed at 80 oC for 2 days under argon atmosphere. Then the solvent was 
Figure 71. Scheme for the synthesis of 11e 
 88 
 
removed under reduced pressure and excess NaBD3CN was quenched using 1M HCl. The 
resulting mixture was neutralized using saturated NaHCO3 solution and concentrated 
under reduced pressure. The residue was purified by silica gel column chromatography 
using chloroform/methanol. Yield: 80%, ESI-MS m/z 372.2 (M+H). 1H NMR (400 MHz, 
CD3OD):  1.49 (s, 9H), 2.12 (s, 3H), 2.18 (s, 3H), 3.64 (m, 3H), 3.76 (m, 2H), 3.92 (m, 
1H), 6.61 (s, 1H), 6.87 (s, 1H) ppm.   
Synthesis of 86a: Boc-protected riboaniline, 85a (100 mg) was stirred in 4(N) 
HCl/dioxane mixture (5 mL) for 4 hrs. The solvent was removed under reduced pressure 
and the remaining mixture was diluted with water followed by extraction with ether. The 
aqueous layer was concentrated to yield the desired product. Yield: 90%. 1H NMR (400 
MHz, CD3OD):  2.30 (s, 3H), 2.31 (s, 3H), 3.62 (m, 1H), 3.72 (m, 4H), 4.08 (m, 1H), 
7.21 (s, 1H), 7.29 (s, 1H) ppm. 
Synthesis of 55e: Compound 86a (1 equiv.), alloxan monohydrate (3 equiv.) and 
boric acid (2 equiv.) were dissolved in 20 mL of acetic acid. The reaction mixture was 
stirred overnight under argon atmosphere and the desired 13C labeled riboflavin (55e) was 
purified by reverse phase high performance liquid chromatography. LC-MS m/z 378.1 
(M+H) (Figure 72). 
Synthesis of 11e: Compound 55e was converted to deuterated FMN (11e) 
enzymatically using RibK from Methanocaldococcus jannaschii. Compound 55e was 
incubated for 30 mins at 70 oC with 5 mM CTP, 20 mM MgCl2 and RibK in 100 mM 
potassium phosphate buffer, pH 7.5. The reaction mixture was passed through a 10kDa 
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cut-off filter and purified by reverse phase high performance liquid chromatography. LC-
MS m/z 458.1 (M+H) (Figure 73).  
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Figure 73. LC-MS analysis of the synthesized deuterated FMN (R:S::3:1). (A) EIC at 458.1182 showing the 
formation of deuterated FMN (B) ESI-MS of 11e in the positive mode 
Figure 72. LC-MS analysis of the synthesized deuterated riboflavin (R:S::3:1). (A) EIC at m/z 378.1518 
showing the formation of deuterated riboflavin (B) ESI-MS of 55e in the positive mode 
55e 
11e 
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5.4.2 Synthesis of deuterated FMN (R:S::1:3) 
The synthetic scheme for 11f is shown in the Figure 74. 
 
 
 
 
 
 
 
 
 
 
 
 
Procedure 
Synthesis of 2-(Boc)amino-4,5-dimethylaniline (84): Compound 84 was 
synthesized following the same procedure used during the synthesis of 13C labeled FMN 
11d (Labeled at C1' position of ribose). 
Synthesis of 85b: Boc-protected aniline, 84 (1 equiv.), D-[1-2H] ribose (3.0 equiv.) 
and sodium cyanoborohydride (2.0 equiv.) were dissolved in anhydrous MeOH (15 mL). 
The mixture was refluxed at 80 oC for 2 days under argon atmosphere. Then the solvent 
Figure 74. Scheme for the synthesis of 11f 
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was removed under reduced pressure and excess NaBH3CN was quenched using 1M HCl. 
The resulting mixture was neutralized using saturated NaHCO3 solution and concentrated 
under reduced pressure. The residue was purified by silica gel column chromatography 
using chloroform/methanol. Yield: 80%, ESI-MS m/z 372.2 (M+H). 1H NMR (400 MHz, 
CD3OD):  1.49 (s, 9H), 2.11 (s, 3H), 2.18 (s, 3H), 3.40 (m, 1H), 3.63 (m, 2H), 3.76 (m, 
2H), 3.92 (m, 1H), 6.60 (s, 1H), 6.87 (s, 1H) ppm.   
Synthesis of 86b: Boc-protected riboaniline, 85b (100 mg) was stirred in 4(N) 
HCl/dioxane mixture (5 mL) for 4 hrs. The solvent was removed under reduced pressure 
and the remaining mixture was diluted with water followed by extraction with ether. The 
aqueous layer was concentrated to yield the desired product. Yield: 90%. 1H NMR (400 
MHz, CD3OD):  2.33 (s, 3H), 2.34 (s, 3H), 3.71 (m, 3H), 3.77 (m, 2H), 4.09 (m, 1H), 
7.34 (s, 1H), 7.43 (s, 1H) ppm. 
Synthesis of 55f: Compound 86b (1 equiv.), alloxan monohydrate (3 equiv.) and 
boric acid (2 equiv.) were dissolved in 20 mL of acetic acid. The reaction mixture was 
stirred overnight under argon atmosphere and the desired 13C labeled riboflavin (55f) was 
purified by reverse phase high performance liquid chromatography. LC-MS m/z 378.1 
(M+H) (Figure 75). 
Synthesis of 11f: Compound 55f was converted to deuterated FMN (11f) 
enzymatically using RibK from Methanocaldococcus jannaschii. Compound 55f was 
incubated for 30 mins at 70 oC with 5 mM CTP, 20 mM MgCl2 and RibK in 100 mM 
potassium phosphate buffer, pH 7.5. The reaction mixture was passed through a 10kDa 
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cut-off filter and purified by reverse phase high performance liquid chromatography. LC-
MS m/z 458.1 (M+H) (Figure 76). 
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Figure 76. LC-MS analysis of the synthesized deuterated FMN (R:S::1:3). (A) EIC at 458.1182 showing the 
formation of deuterated FMN (B) ESI-MS of 11f in the positive mode 
 
Figure 75. LC-MS analysis of the synthesized deuterated riboflavin (R:S::1:3). (A) EIC at m/z 378.1518 
showing the formation of deuterated riboflavin (B) ESI-MS of 55f in the positive mode 
11f 
55f 
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CHAPTER VI 
SUBSTRATE ANALOG STUDIES WITH 8-SUBSTITUTED FLAVIN 
 
6.1 Introduction 
 The formation of flavin hydroperoxide (15) has been proposed as the first step in 
DMB biosynthesis in all the mechanistic proposals in the literature based on the BluB 
crystal structure. Evidence for its formation has been provided using stopped-flow studies. 
It has been reported that the peroxyflavin formation in BluB is both enzyme and oxygen 
dependent55. The formation of flavin peroxide intermediate has been observed to be very 
rapid (in the order of milliseconds) whereas its decay is seen to be comparatively slower 
being in the order of seconds. It has also been reported that the decay occurs in a biphasic 
manner as the peroxy species decays in productive (leading to DMB formation) as well as 
non-productive manner (giving back oxidized flavin). 
The flavin hydroperoxide (15) thus formed undergoes unusual fragmentation 
leading to a C-C bond cleavage between the C1' and C2' of the ribose sugar chain. In the 
mechanism A proposed in the literature (Figure 6), the fragmentation is initiated by 
hydroxylation at C1' of the ribityl chain assisted by the deprotonation at C1' using the Asp-
32 residue. This seems to be very difficult as a large conformational change in the active 
site would be required for hydroxylation at C1' and even the Asp-32 is not a strong enough 
base to carry out this transformation. On the other hand, in the mechanism B (Figure 7), 
fragmentation of the peroxy moiety occurs by a hydride transfer from the hydroxyl group 
at C2' position of the ribityl tail. Such a hydride transfer is highly unlikely as the hydroxyl 
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groups are typically not known to form hydride ions. Thus, the fragmentation steps 
proposed in both these mechanisms seem to be very difficult and challenging15. 
In our current mechanistic hypothesis (Figure 67), we have proposed that the flavin 
hydroperoxide (15) undergoes fragmentation forming the intermediate 47 followed by C-
C bond cleavage and further chemistry to ultimately form DMB. To explore this unusual 
fragmentation of the flavin, substrate analog studies were done using 8-substituted flavins. 
 
6.2 Results and discussion 
6.2.1 Identification of the shunt product 100 
 Enzymatic reactions with the 8-substituted flavins (8-OH FMN and 8-NH2 FMN) 
provided interesting results. Formation of the usual products (5-OH DMB (99), erythrose-
4-phosphate and alloxan) following the native chemistry was observed on carrying out 
BluB catalyzed reactions using 8-OH FMN (Figure 77).  
 
 
 
 
 
 
 
 
A) B) 
147.0560 
Figure 77. BluB catalyzed reaction with 8-OH FMN. (A) HPLC chromatogram at 280 nm showing the formation 
of 5-OH DMB (99) (B) ESI-MS of 99 in the negative mode 
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The formation of 5-OH DMB (99) was confirmed by co-eluting it with a 
synthesized standard (Figure 78)56. 
 
 
 
 
 
 
 
 
Along with the formation of the native products, a new peak was also observed at 
450 nm in the HPLC analysis of the BluB catalyzed reactions using 8-OH FMN (Figure 
79A). The new peak had a UV-Vis spectrum similar to that of the substrate (8-OH FMN) 
and a mass corresponding to 316 Da (Figure 79B). Based on the mass and MS-MS 
fragmentation pattern (Figure 80), we assigned 100 to be the structure for the new shunt 
product formed. 
 
 
 
 
Figure 78. Co-elution data for the formation of 5-OH DMB using 8-OH FMN as substrate analog 
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To confirm the structure of 100, the new shunt product formed was collected, 
treated with sodium borohydride and was then coeluted with the synthesized alcohol 
standard, 101 (Figure 81).  
 
B) 
315.0735 
A) 
172.0515 
200.0466 
243.0527 
Figure 80. MS-MS fragmentation pattern of 100 in the negative mode 
Figure 79. BluB catalyzed reaction with 8-OH FMN. (A) Formation of the shunt product 100 using 8-OH 
FMN as substrate (B) ESI-MS of 100 in the negative mode 
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Figure 82. LC-MS analysis of the derivatization of the shunt product 100. (A) EIC at m/z 512.0988 showing 
the derivatization of 100 using PFBHA into its corresponding oxime (102) only in case of full reaction (Red 
trace) (B) ESI-MS of 102 in the positive mode 
 
 
 
 
 
 
 
 
 
 
To establish the presence of an aldehyde group in 100, the reaction mixture was 
derivatized using o-pentafluorobenzylhydroxylamine (PFBHA) to convert 100 into its 
corresponding oxime (102). Formation of 102 was seen only in case of the full reaction 
treated with PFBHA and was absent in all the other controls (Figure 82) which confirms 
that the shunt product 100 contains an aldehydic group.  
 
 
A) B) 
317.0892 
Figure 81. Coelution data for the shunt product 100. (A) Coelution study after borohydride treatment of 100 
(B) ESI-MS of the compound (101) formed on borohydride reduction of 100 in the negative mode 
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6.2.2 Identification and trapping of glycolaldehyde-2-phosphate (105) 
The shunt compound 100 thus formed contains only three carbons in the sugar side 
chain as compared to five carbons in the ribose chain of the substrate, 8-OH FMN. The 
remaining two carbon fragment was identified as glycolaldehyde-2-phosphate (105) using 
a similar strategy of trapping it in its corresponding oxime form (103) using PFBHA 
(Figure 83).  
 
 
 
  
 
 
 
 
 
Formation of glycolaldehyde-2-phosphate (105) was further confirmed by carrying 
out CIP treatment of the reaction mixture treated with PFBHA (Figure 84) and then 
coeluting it with the synthesized standard 104 (Figure 85)57. 
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Figure 83. LC-MS analysis for the trapping of glycolaldehyde-2-phosphate. (A) EIC at 336.0055 showing 
the trapping of glycolaldehyde-2-phosphate using PFBHA in the form of oxime (103) only in case of full 
reaction (Red trace) (B) ESI-MS of 103 in the positive mode 
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6.2.3 Summary of the BluB reaction with 8-OH FMN 
Thus, the reaction of BluB with 8-OH FMN leads to the formation of 100 and 105 
following an unusual C-C bond fragmentation between the C3' and C4' of the ribose sugar 
chain apart from forming the usual products (Figure 86). Similar results were also obtained 
on using 8-NH2 FMN as a substrate analog. 
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Figure 84. LC-MS analysis after the CIP treatment of 103. (A) EIC at 256.0391 showing the loss of the 
phosphate group on CIP treatment of glycolaldehyde-2-phosphate – PFBHA oxime (103) (B) ESI-MS of 
104 in the positive mode 
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Figure 85. LCMS analysis for the coelution of PFBHA derivatized oxime of glycolaldehyde (104) 
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6.2.4 Mechanistic proposal for the formation of the shunt product 100 
 Our current mechanistic hypothesis for the formation of the shunt product 100 is 
shown in Figure 87. Our proposal is that the reduced form of 8-OH FMN (107) first reacts 
with oxygen to form the flavin hydroperoxide intermediate (108) which undergoes 
fragmentation to form 110 via intermediate 109. The peroxide fragmentation forms the 
intermediate 111 which undergoes the usual C-C bond fragmentation between the C1' and 
C2' of the ribose sugar chain forming the native products (5-OH DMB (99), erythrose-4-
phosphate and alloxan). However, 111 can also tautomerize to form 113 via 112 which 
further undergoes keto-enol tautomerization to form intermediate 114. 114 then undergoes 
a C-C bond fragmentation between the C3' and C4' of the sugar chain in a retro-aldol 
manner forming glycolaldehyde-2-phosphate (105) and 115. The intermediate 115 
tautomerizes to form 116 which finally cyclizes forming the shunt product 100. 
Figure 86. Summary of the BluB catalyzed reaction with 8-OH FMN (106) 
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 We propose that the substitution of the methyl with a hydroxyl group at the 8 
position of the substrate leads to a conformational change in the active site of the enzyme. 
This leads to the unusual fragmentation between the C3' and C4' of the sugar chain besides 
the usual C-C bond cleavage chemistry leading to DMB. 
The identification and characterization of the shunt product 100 help us provide 
evidence for the existence of the intermediate 47 (Figure 21) which is formed from the 
fragmentation of the peroxyflavin moiety (15) during DMB formation. This serves as 
Figure 87. Mechanistic proposal for the formation of 100 
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evidence for the initial fragmentation step of the flavin peroxide intermediate involved in 
the DMB biosynthesis. 
 
6.3 Conclusion 
 BluB catalyzed reactions using 8-substituted flavin as substrate yielded unusual 
results. Along with the formation of the native products, a new shunt product (100) was 
also observed. The observed shunt product is formed as a result of a C-C bond 
fragmentation between the C3' and C4' of the ribose sugar chain. The identification of this 
shunt product provides evidence for the initial peroxyflavin fragmentation step involved 
in the formation of dimethylbenzimidazole.  
 
6.4 Experimental 
6.4.1 PFBHA derivatization of shunt product 100 and glycolaldehyde-2-phosphate 
BluB enzymatic reactions were performed in 100 mM phosphate buffer, pH 7.5 
containing BluB (100 μM), 8-OH FMN (300 μM) and dithionite. The enzymatic reactions 
were incubated at room temperature for 4 hrs. The protein was then removed by heat 
denaturation and o-(pentafluorobenzyl)hydroxylamine (PFBHA) (2mM) was added to the 
reaction mixture and was heated at 65 oC for 1 hr. The reaction mixture was then analyzed 
by LC-MS. 
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6.4.2 Borohydride reduction of the shunt product 100 
The shunt product 100 was collected in the HPLC and was then lyophilized. The 
sample was then dissolved in anhydrous THF and was treated with sodium borohydride at 
room temperature. After 2 hrs, the solvent THF was removed under vacuum and the sample 
was dissolved back in phosphate buffer. The reaction mixture was then analyzed by HPLC 
and LC-MS. 
 
6.4.3 CIP treatment of glycolaldehyde-2-phosphate – PFBHA oxime (103) 
BluB enzymatic reactions were performed in 100 mM phosphate buffer, pH 7.5 
containing BluB (100 μM), 8-OH FMN (300 μM) and dithionite. The enzymatic reactions 
were incubated at room temperature for 4 hrs. The protein was removed by heat 
denaturation and o-(pentafluorobenzyl)hydroxylamine (PFBHA) (2mM) was added to the 
reaction mixture and was heated at 65 oC. After an hour, the reaction mixture was 
incubated with CIP at 37 oC for 2 hrs. The reaction mixture was then analyzed by LC-MS. 
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6.4.4 Synthesis of 8-OH FMN (106)58 
The synthetic scheme for 8-OH FMN (106) is shown in Figure 88. 
 
 
 
 
 
 
 
Procedure 
Synthesis of 5-((3-Hydroxy-4-methylphenyl)amino)pentane-1,2,3,4-tetraol 
(118): 5-Amino-2-methylphenol, 117 (123 mg, 1.0 equiv.), D-ribose (450 mg, 3.0 equiv.) 
and sodium cyanoborohydride (126 mg, 2.0 equiv.) were dissolved in anhydrous MeOH 
(15 mL). The mixture was refluxed at 80 oC for 2 days under argon atmosphere. Then the 
solvent was removed under reduced pressure and excess NaBH3CN was quenched using 
1M HCl. The resulting mixture was neutralized using saturated NaHCO3 solution and 
concentrated. The residue was purified by silica gel column chromatography using 
chloroform/methanol. Yield: 65%, LC-MS m/z 258.1 (M+H). 1H NMR (400 MHz, 
CD3OD):  2.04 (s, 3H), 3.39 (dd, 1H), 3.64 (m, 3H), 3.78 (m, 2H), 3.90 (m, 1H), 6.16 
Figure 88. Scheme for the synthesis of 8-OH FMN (106) 
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(dd, 1H), 6.21 (d, 1H), 6.79 (d, 1H), 7.80 (s, 1H) ppm. 13C NMR (100 MHz, CD3OD):  
15.3, 64.2, 72.0, 73.9, 74.7, 79.3, 102.0, 106.8, 114.9, 131.9, 149.0, 156.6 ppm. 
Synthesis of 8-Hydroxyriboflavintetraacetate (120): To a solution of 118 (258 mg, 
1 equiv.) in 15 mL of water, violuric acid monohydrate (175 mg, 1 equiv.) and boric acid 
(62 mg, 1 equiv.) were added. The mixture was refluxed at 105 oC for 12 hours and was 
then concentrated under reduced pressure. The crude product was dissolved in 8 mL of 
pyridine. 1 mL of acetic anhydride was added to the mixture and was stirred at rt for 6 hrs. 
The solvent was then removed under reduced pressure with toluene. The residue was 
purified by silica gel column chromatography using chloroform/methanol. LC-MS m/z 
547.2 (M+H). 1H NMR (400 MHz, CD3OD):  1.73 (s, 3H), 2.01 (s, 3H), 2.14 (s, 3H), 
2.20 (s, 3H), 2.30 (s, 3H), 3.49 (m, 1H), 3.59 (q, 1H), 4.09 (q, 1H), 4.26 (dd, 1H), 4.46 (dd, 
1H), 5.38 (m, 1H), 5.50 (m, 1H), 5.70 (m, 1H), 6.95 (s, 1H), 7.78 (s, 1H) ppm. 
Synthesis of 8-Hydroxyriboflavin (119): Compound 120 was converted to 8-
Hydroxyriboflavin (119) by overnight stirring in ammonia (7N in methanol) and was 
purified by reverse phase high performance liquid chromatography. LC-MS m/z 379.1 
(M+H) (Figure 89A and B). 
Synthesis of 8-Hydroxyflavinadeninedinucleotide (121): Compound 119 was 
converted to 8-OH FAD (121) enzymatically using FAD synthetase from 
Corynebacterium ammoniagenes. 8-OH riboflavin was incubated overnight at 37 oC with 
5 mM ATP, 20 mM MgCl2 and FAD synthetase in 100 mM phosphate buffer, pH 7.5. The 
reaction mixture was passed through a 10kDa cut-off filter and purified by reverse phase 
high performance liquid chromatography. LC-MS m/z 788.1 (M+H) (Figure 89C and D). 
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Synthesis of 8-Hydroxyflavinmononucleotide (106): 8-OH FAD (121) purified by 
HPLC was incubated for 2 hrs at 37 oC with 2-3 mg of phosphodiesterase I from Crotalus 
atrox (Western Diamondback Rattlesnake) in 10 mL of 100 mM potassium phosphate 
buffer, pH 7.5. The reaction mixture was passed through a 10kDa cut-off filter and then 
purified by reverse phase high performance liquid chromatography to yield the final 
compound 8-OH FMN (106). LC-MS m/z 459.1 (M+H) (Figure 90).  
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Figure 89. LC-MS analysis of the synthesized 8-OH Riboflavin and 8-OH FAD. (A) UV chromatogram at 
450 nm showing the formation of 8-OH Riboflavin (B) ESI-MS of 119 in the positive mode (C) EIC at m/z 
788.1437 showing the formation of 8-OH FAD (D) ESI-MS of 121 in the positive mode 
119 
121 
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6.4.5 Synthesis of 5-OH DMB (99)56 
The synthetic scheme for 5-OH DMB (99) is shown in Figure 91. 
 
 
 
 
 
 
 
 
 
Figure 91. Scheme for the synthesis of 5-OH DMB (99) 
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Figure 90. LC-MS analysis of the synthesized 8-OH FMN. (A) EIC at m/z 459.0912 showing the formation 
of 8-OH FMN (B) ESI-MS of 106 in the positive mode 
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Procedure 
Synthesis of 5-Methoxy-4-methyl-2-nitroaniline (123): 3-Methoxy-4-
methylaniline, 122 (137 mg, 1.0 equiv.) was dissolved in 5 mL of conc. H2SO4 and the 
solution was cooled to -5 oC. To this, a solution of NaNO3 (85 mg, 1.0 equiv.) in 2.5 mL 
of conc. H2SO4 was slowly added with the temperature being maintained below -3 
oC. 
After stirring the mixture for 15 mins, it was poured on ice and 25 mL of water was then 
added to it. The precipitate was collected by filtration. Yield: 40%, LC-MS m/z 183.1 
(M+H). 1H NMR (400 MHz, CDCl3):  2.07 (s, 3H), 3.82 (s, 3H), 5.57 (s, 2H), 6.12 (s, 
1H), 7.86 (s, 1H) ppm. 13C NMR (100 MHz, CDCl3):  15.2, 55.8, 98.0, 118.5, 126.2, 
127.3, 144.9, 164.1 ppm. 
Synthesis of 4-Methoxy-5-methylbenzene-1,2-diamine (124): 5-Methoxy-4-
methyl-2-nitroaniline, 123 (100 mg) was dissolved in 50 mL MeOH and passed through a 
Thalesnano H-cube hydrogenator with 10% Pd/C catalyst at 40 oC and 1 bar hydrogen gas 
pressure at a flow rate of 1.0 mL/min. The solution was then concentrated under reduced 
pressure and the resulting compound was used for the next step without further 
purification. Yield: 85%, LC-MS m/z 153.1 (M+H). 1H NMR (400 MHz, CD3OD):  2.01 
(s, 3H), 3.68 (s, 3H), 6.36 (s, 1H), 6.51 (s, 1H) ppm.   
Synthesis of 5-Methoxy-6-methylbenzimidazole (125): 4-Methoxy-5-
methylbenzene-1,2-diamine (124) was dissolved in 2 mL of HCOOH and the solution was 
refluxed for 2 hrs. The reaction mixture was then diluted with water and extracted with 
CHCl3. The pH of the aqueous phase was adjusted to 8 using ammonium hydroxide and 
was then extracted with CHCl3. The organic phase was concentrated under reduced 
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pressure and purified by silica gel column chromatography. Yield: 35%, LC-MS m/z 163.1 
(M+H). 1H NMR (400 MHz, CD3OD):  2.26 (s, 3H), 3.83 (s, 3H), 7.04 (s, 1H), 7.32 (s, 
1H), 7.98 (s, 1H) ppm. 13C NMR (100 MHz, CD3OD):  17.1, 56.1, 96.5, 117.0, 124.5, 
132.7, 137.3, 140.9, 156.6 ppm. 
Synthesis of 5-Hydroxy-6-methylbenzimidazole (99): 5-Methoxy-6-methyl 
benzimidazole (125) was dissolved in 2.5 mL of hydrobromic acid and the solution was 
refluxed for 1 hr. The reaction mixture was then diluted with water and the pH was adjusted 
to 8 using ammonium hydroxide followed by purification using silica gel column 
chromatography. Yield: 80%, LC-MS m/z 149.1 (M+H). 1H NMR (400 MHz, CD3OD):  
2.27 (s, 3H), 7.04 (s, 1H), 7.31 (s, 1H), 8.04 (s, 1H) ppm. 13C NMR (100 MHz, CD3OD): 
 17.0, 99.7, 117.0, 123.1, 132.5, 136.4, 140.8, 153.4 ppm. 
 
6.4.6 Synthesis of the compound 101 
The synthetic scheme for 101 is shown in Figure 92.  
 
 
 
 
 
 
Figure 92. Scheme for the synthesis of 101 
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Procedure 
Synthesis of 3-((3-Hydroxy-4-methylphenyl)amino)propane-1,2-diol (126): 5-
Amino-2-methylphenol, 117 (123 mg, 1.0 equiv.), glyceraldehyde (270 mg, 3.0 equiv.) 
and sodium cyanoborohydride (126 mg, 2.0 equiv.) were dissolved in anhydrous MeOH 
(15 mL). The mixture was refluxed at 80 oC for 2 days under argon atmosphere. Then the 
solvent was removed under reduced pressure and excess NaCNBH3 was quenched using 
1M HCl. The resulting mixture was neutralized using saturated NaHCO3 solution and 
concentrated under reduced pressure. The residue was purified by silica gel column 
chromatography using chloroform/methanol. Yield: 60%, LC-MS m/z 198.1 (M+H). 1H 
NMR (400 MHz, CD3OD):  2.05 (s, 3H), 2.99 (dd, 1H), 3.19 (dd, 1H), 3.57 (m, 2H), 3.81 
(p, 1H), 6.13 (dd, 1H), 6.18 (d, 1H), 6.80 (d, 1H) ppm. 13C NMR (100 MHz, CD3OD):  
15.3, 48.3, 65.5, 71.6, 101.7, 106.5, 114.7, 132.0, 149.1, 156.6 ppm. 
Synthesis of 127: To a solution of 126 (197 mg, 1 equiv.) in 15 mL of water, 
violuric acid monohydrate (175 mg, 1 equiv.) and boric acid (62 mg, 1 equiv.) were added. 
The mixture was refluxed at 105 oC for 12 hours and was then concentrated under reduced 
pressure. The crude product was dissolved in 8 mL of pyridine. 1 mL of acetic anhydride 
was added to the mixture and was stirred at rt for 6 hrs. The solvent was then removed 
under reduced pressure with toluene. The residue was purified by silica gel column 
chromatography using chloroform/methanol. LC-MS m/z 401.1 (M-H). 1H NMR (400 
MHz, CD3OD):  1.78 (s, 3H), 2.09 (s, 3H), 2.21 (s, 3H), 4.38 (m, 2H), 4.69 (m, 1H), 5.56 
(m, 1H), 5.70 (br, 1H), 6.78 (s, 1H), 7.61 (s, 1H) ppm. 13C NMR (100 MHz, CD3OD):  
 111 
 
16.5, 20.5, 20.6, 46.2, 64.5, 70.3, 100.9, 126.0, 134.0, 134.2, 134.9, 138.0, 152.0, 159.1, 
163.5, 163.9, 171.9, 172.4 ppm. 
Synthesis of 101: Compound 127 was converted to compound 101 by overnight 
stirring in ammonia (7N in methanol) and was purified by reverse phase high performance 
liquid chromatography. LC-MS m/z 317.1 (M-H) (Figure 93). 
 
 
 
 
 
 
 
 
 
 
6.4.7 Synthesis of glycolaldehyde-PFBHA oxime (104)57 
The synthetic scheme for the glycolaldehyde-PFBHA oxime (104) is shown in 
Figure 94. 
 
 
Figure 94. Scheme for the synthesis of glycolaldehyde-PFBHA oxime (104) 
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Figure 93. LC-MS analysis of the synthesized compound 101. (A) EIC at m/z 317.0891 showing the 
formation of 101 (B) ESI-MS of 101 in the negative mode 
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Procedure 
Synthesis of glycolaldehyde-PFBHA oxime (104): Glycolaldehyde dimer, 128 (1 
mM) and o-(pentafluorobenzyl)hydroxylamine (PFBHA, 41) (2mM) were mixed in 500 
mM NH4OAc buffer, pH 8.6. The reaction mixture was heated at 65 
oC for 1 hr and was 
then analyzed by LC-MS (Figure 95).  
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Glycoaldehyde + PFBHA std dil_1-C,6_01_32257.d: EIC 256.0397±0.01 +All MS
A) 
  6                     1                        2                       2                        2                   Time (mins)   
Intens. 
x 10
4 
1.5 
1.0 
0.5 
0.0 
Glycolaldehyde - PFBHA oxime 
standard 
B) 
256.0392 
Figure 95. LC-MS analysis for the synthesized glycolaldehyde - PFBHA oxime (104). (A) EIC at 256.0391 
showing the formation of the glycolaldehyde – PFBHA oxime standard (B) ESI-MS of 104 in the positive 
mode 
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CHAPTER VII 
SUMMARY 
 
BluB catalyzes the oxygen dependent biosynthesis of Dimethylbenzimidazole 
(DMB) from reduced FMN. It involves a remarkable rearrangement in which the C1 ' of 
the ribityl side chain of FMN is incorporated at C2 of the product, DMB (13).  
In this dissertation, we have successfully identified alloxan (29) as the final end 
product derived from the ring C of FMN. Formation of alloxan was confirmed by trapping 
it as an adduct using the derivatizing agent oPDA. Water and oxygen gas have been shown 
to be the two sources of oxygen atom incorporation in the alloxan based on O-18 labeling 
studies. The sugar end product, erythrose-4-phosphate (14) was successfully derivatized 
using PFBHA in the form of its corresponding oxime. 
A key intermediate (27) in our mechanistic proposal has been successfully trapped 
in the form of six different shunt products using water, bisulfite and hydride as 
nucleophiles. Presence of the imine functionality in the intermediate 27 was confirmed by 
trapping it with bisulfite as well as reducing it with cyanoborohydride and deuterium 
studies. Detailed characterization of the various shunt products was done by coelution and 
labeling studies.  
Trapping of the intermediate 27 helps us establish the actual sequence of the release 
of the different products in the BluB catalyzed reaction. Presence of the alloxan moiety in 
27 proves that the C-C bond cleavage occurs first forming erythrose-4-phosphate (14) 
followed by the release of alloxan (29).  
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Asp-32 has been shown to play an important role in stabilizing this intermediate 
by forming an adduct and its mutation to asparagine (D32N mutant) leads to the exclusive 
formation of the different shunt products.  
 Characterization of the shunt product 73 provides evidence for the intermediate 35 
in our mechanistic hypothesis. It also helps us establish that the alloxan is released first 
followed by the cyclization and oxidation steps leading to the formation of DMB. 
Based on the stereochemical studies, we have successfully shown that the pro-R 
hydrogen is abstracted from the C1' of the ribose sugar chain of the substrate and the pro-
S hydrogen is retained in the final product, DMB. Thus, there exists a selectivity in the 
abstraction of the proton from the C1' of the ribityl chain of FMN. This result helps us 
establish that the final oxidation step leading to DMB is indeed catalyzed by the enzyme.  
Substrate analog studies were also performed for the BluB catalyzed reaction. 
Interesting results were obtained on using 8-substituted flavins as substrates. Along with 
the formation of the native products, a new shunt product (100) was observed in the BluB 
reactions with 8-OH FMN. An unusual C-C bond fragmentation between C3' and C4' of 
the ribose sugar chain of FMN leads to the formation of the shunt product 100 along with 
glycolaldehyde-2-phosphate as the other fragment. Characterization of 100 provides 
evidence for the initial fragmentation of the peroxyflavin intermediate involved in the 
biosynthesis of dimethylbenzimidazole. 
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All these above observations are consistent with our current mechanistic proposal 
for the DMB biosynthesis as shown in Figure 96. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 96. Final mechanistic proposal for the formation of Dimethylbenzimidazole 
 116 
 
Thus, we have been thus able to provide multiple pieces of evidence in support of 
our mechanistic proposal for DMB formation and have finally unraveled the long unsolved 
mystery in the vitamin B12 biosynthesis. 
 Interestingly, the two pathways involved in the DMB formation are distinctly 
different. In the anaerobic organisms, BzaF carries out the benzimidazole formation 
involving complex radical mediated chemistry. Identification and successful reconstitution 
of BzaF is a major stepping stone in the anaerobic biosynthesis of benzimidazole. On the 
other hand, in the aerobic pathway BluB is responsible for the DMB biosynthesis involving 
unique flavochemistry. Reduced FMN is the substrate of BluB which undergoes 
unprecedented rearrangement to form DMB. It is a unique example, wherein, destruction 
of one cofactor leads to another. 
It is amazing to see how subtle changes in the active site leads to an entirely 
different functionality. Though being structurally similar to the flavin reductase 
superfamily, BluB carries out completely different chemistry as compared to the 
oxidoreductases and nitroreductases.  
In general, identification of the various shunt products formed can help us provide 
snapshots of the reaction coordinates in a multi-step reaction. With the advancement in the 
field of mass spectrometry, the characterization of these shunt products is no longer 
difficult. BluB, serves as a good example, wherein, identification of the various shunt 
products helped us decode the complex transformation involved in DMB biosynthesis. 
This can serve as a general tool to elucidate the detailed mechanism involved in various 
complex enzymatic reactions. 
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 APPENDIX 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure A1. 13C NMR of Riboflavin isotopologues (A) 4a-13C Riboflavin (55a) (B) 2-13C Riboflavin (55b) 
(C) 4,10a-13C Riboflavin (55c) 
PPM   160.0    140.0    120.0    100.0    80.0     60.0     40.0     20.0   
C) 
PPM   160.0    140.0    120.0    100.0    80.0     60.0     40.0     20.0   
A) 
PPM   160.0    140.0    120.0    100.0    80.0     60.0     40.0     20.0   
B) 
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Figure A2. 1H and 13C NMR of alloxan-oPDA adduct (40) 
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Figure A3. 1H and 13C NMR of 5,6-Dimethyl-2-hydroxymethylbenzimidazole (77) 
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Figure A4. 1H and 13C NMR of N-Carbamoyl-5,6-dimethylbenzimidazole-2-carboxamide (56) 
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Figure A5. 1H and 13C NMR of N-Methyl-4,5-dimethyl-2-nitrobenzenamine (80) 
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Figure A6. 1H and 13C NMR of N-Methyl-4,5-dimethylbenzene-1,2-diamine (81) 
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Figure A7. 1H and 13C NMR of 1,5,6-Trimethyl-2-hydroxymethylbenzimidazole (82) 
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Figure A8. 1H and 13C NMR of 1,5,6-Trimethylbenzimidazole-2-carboxylic acid (83) 
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Figure A9. 1H NMR of N-Carbamoyl-1,5,6-trimethylbenzimidazole-2-carboxamide (58) 
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Figure A10. 1H and 13C NMR of 2-(Boc)amino-4,5-dimethylaniline (84) 
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Figure A11. 1H NMR of 85 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A12. 1H NMR of 86 
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Figure A13. 1H and 13C NMR of 88 
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Figure A14. 1H and 13C NMR of 89 
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Figure A15. 1H and 13C NMR of 8-Aminoriboflavintetraacetate (90) 
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Figure A16. 1H and 13C NMR of 8-Aminoflavinmononucleotide (93) 
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Figure A17. 1H and 13C NMR of 4-Methylbenzene-1,3-diamine (94) 
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Figure A18. 1H and 13C NMR of 8-NH2 lumichrome (70) 
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Figure A19. 1H and 13C NMR of 73 
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Figure A20. 1H NMR of 85a 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A21. 1H NMR of 86a 
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Figure A22. 1H NMR of 85b 
 
 
 
 
 
 
 
 
 
 
 
Figure A23. 1H NMR of 86b 
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Figure A24. 1H and 13C NMR of 118 
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Figure A25. 1H and 13C NMR of 8-Hydroxyriboflavintetraacetate (120) 
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Figure A26. 1H and 13C NMR of 5-Methoxy-4-methyl-2-nitroaniline (123) 
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Figure A27. 1H NMR of 4-Methoxy-5-methylbenzene-1,2-diamine (124) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A28. 1H and 13C NMR of 5-Methoxy-6-methylbenzimidazole (125) 
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Figure A29. 1H and 13C NMR of 5-OH DMB (99) 
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Figure A30. 1H and 13C NMR of 126 
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Figure A31. 1H and 13C NMR of 127 
